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ABSTRACT 
Gender disparities in the diagnosis of cardiovascular diseases have been well 
established. Not much is known about gender differences in obstructive airway diseases 
(OADs).  The aim of this thesis is to 1) conduct a systematic review and meta-analysis to 
synthesize the existing evidence on gender bias in the diagnosis of chronic obstructive 
pulmonary disease (COPD), 2) conduct a secondary data analysis to examine gender 
diagnostic bias in patients who meet spirometry criteria for COPD and 3) conduct a 
secondary data analysis to examine gender diagnostic bias in patients who meet spirometry 
criteria for asthma.  
The Cochrane handbook for systematic reviews of interventions was used as a guide 
for standard methods used in systematic reviews. Literature search was conducted using 
MEDLINE (PubMed), EMBASE and CINAHL. Relevant articles were selected for 
descriptive and quantitative synthesis, and the Inverse Variance (IV) random effect model 
was used for analysis. For the secondary data analysis, multivariate logistic regression was 
used to assess the effect of sex on diagnostic outcomes (physician-diagnosed COPD or 
physician-diagnosed asthma, misdiagnosis, referral to a specialist, referral for spirometry and 
referral for chest x-ray), while controlling for additional patient factors. 
Results from the meta-analysis suggests that gender disparities do exist in primary 
care for COPD, as men were about two times more likely to receive a correct diagnosis for 
COPD, and women with respiratory symptoms were less likely to be referred for spirometry. 
For the secondary analysis of data, no significant differences between genders were observed 
for all diagnostic outcomes in patients who meet spirometry criteria for COPD. However, for 
patients with spirometrically-defined asthma, women were less likely than men to receive a 
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correct diagnosis for asthma, less likely to be referred for spirometry, but more likely than 
men to be referred for chest-x-ray.      
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CHAPTER ONE 
Introduction 
1.1 Background 
1.1.1 Obstructive Airway Diseases remain a Global Burden 
Obstructive airway diseases (OADs) are also called obstructive lung diseases. They are a 
category of respiratory diseases characterized by airway obstruction. Many OADs result from 
narrowing or loss of elastic recoil of the lower airway tubes and may be characterized 
by inflamed and easily collapsible airways, shortness of breath, chest tightness, problems 
exhaling and frequent medical clinic visits and hospitalizations (1, 2). Amongst the conditions 
that fall under the category of OADS (asthma, bronchiectasis, COPD [chronic bronchitis and 
emphysema]) asthma and COPD represent the most significant diseases based on high 
prevalence and health care system burden (1-3). Asthma and COPD also represent the most 
common cases of respiratory diseases worldwide (4).  
Prevalence of asthma is increasing globally (4, 5). The disease prevalence in Canada has 
been increasing over the last 20 years, and it is estimated that currently, over three million 
Canadians have asthma (5, 6). The prevalence of COPD is also rising, and reports predict that by 
the year 2030, COPD will be the third most common cause of mortality worldwide (6). The 
burden asthma and COPD pose to Canada’s economy is large (3, 5, 6). The two conditions 
negatively impact the lives of Canadians in terms of their mental health, limitations to activities 
of daily living, work, and social and recreational activities. Chronic lung diseases account for 
more than 6% of  health care costs annually in Canada (5,6). The cost associated with asthma is 
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estimated at CAD648 million per year (5), while direct and indirect costs of COPD are estimated 
at CAD1997.81 per patient annually (3, 5, 6). Existing data on obstructive airway disease 
prevalence suggests a high burden on primary care, which is the first healthcare contact for most 
patients with respiratory diseases (7).  
COPD and asthma share similar symptoms, such as chronic cough, wheezing, chest 
tightness, sputum production, and difficulty in breathing (8, 9). Nonetheless, they are distinct 
conditions with different etiology, frequency of symptoms and reversibility of airway obstruction 
(8, 9). COPD is said to be an adult-onset disease and results in a progressive permanent damage 
to the lower airways, usually as a result of excessive smoking (2). Asthma, on the other hand, is 
typically diagnosed in children and has been linked to an immune response to allergen exposure 
(1). Though they share similar symptoms, the symptoms may be experienced differently. For 
instance, patients with COPD are more likely to experience an early morning cough with 
increased sputum production and persistent symptoms. On the other hand, symptoms 
experienced by asthma patients are more likely to be episodic or may occur at night. Unlike 
COPD, airflow obstruction in asthma can usually be reversed by medications (1, 2). 
The differential diagnosis of asthma and COPD was much easier historically, as COPD 
used to be a disease of older men who smoked (10). In recent times, however, many women and 
youth are also smoking, and this has made it difficult to differentiate between the two conditions 
(11).  There are currently several guidelines that provide directions for diagnosis and treatment 
of asthma and COPD (1, 2). Nonetheless, both diseases remain underdiagnosed, misdiagnosed 
and undertreated (12). Early diagnosis is vital due to profound differences between asthma and 
COPD in treatment and disease progression (12). There is evidence that about 80% of COPD 
cases are undiagnosed until the latter stages of the disease when severe organ damage has 
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occurred (13-16). Interestingly, there are many patients in primary care who have been 
diagnosed with asthma when in fact they have COPD and vice versa (17-19).  
1.1.2 The Issue of Diagnostic Bias  
Gender inequalities in healthcare service utilization have been discussed for many years. 
Despite the best intentions of health workers to provide standard treatment to all, gender 
disparities in health care persist, and this may lead to an unwarranted increase in morbidity and 
mortality for some patients (20). Many factors may be responsible for these disparities, including 
implicit bias (an unintentional, unconscious attribution of particular qualities to a particular 
social group) usually influenced by experience, intuition or prejudice (20, 21). “Implicit bias may 
contribute to health care disparities by shaping physician behavior and producing differences in 
medical treatment along the lines of race, ethnicity, gender or other characteristics”- Elizabeth N. 
Chapman, MD (20).  A bias in diagnosis arises when medical and psychological diagnosis is 
influenced by the sex of the patient consciously or unconsciously, resulting in unequal medical 
practices for men and women (20, 21). Gender differences in referral for diagnostic tests have 
been identified in other chronic diseases like heart diseases, depression and autoimmune 
disorders (22, 23).  
Evidence for gender bias in the diagnosis of cardiovascular diseases is extensive (22-25). 
Heart diseases have been considered for many years as a disease of men (26).  The notion that 
women could suffer more from breast cancer than from cardiovascular diseases has been deeply 
ingrained, and this may put women at risk of underdiagnosis (26). Young women with 
cardiovascular diseases are often treated late, or the diagnosis may be missed entirely (26, 27). 
Evidence suggests that if a woman and man presented to the emergency clinic with symptoms 
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characteristic of a heart attack, the woman is less likely to undergo diagnostic catheterization 
(aRR=0.75, 95%CI: 0.68-0.83) and also less likely to be given a thrombolytic therapy 
(aRR=0.93, 95%CI: 0.90-0.96) within 60 minutes of admission, as compared to her male 
counterpart (25). In the inpatient setting, studies of women with stroke have reported longer wait 
times on arrival at the emergency department, coupled with less aggressive treatment and less 
therapeutic workup during admission (28-30). Studies conducted in North America and Europe 
have found women with cardiovascular diseases to be less likely than men to receive appropriate 
diagnostic imaging or carotid revascularization (31-34).  
Subsequently, the risk of heart diseases in women has been underestimated, under-
recognized and underdiagnosed, leading to less aggressive treatment strategies, an increase in 
mortality and lower numbers of women being represented in clinical trials (35). Ironically, 
women are as likely as men to have heart failure (36). Moreover, women with heart failure have 
higher mortality rates than men with the same condition (36). 
Gender disparities have also been seen for depression (37). In developed countries, 
women are twice as likely as men to be diagnosed with depression, even though higher rates of 
successful suicides have been recorded in men with depression (37). Men with depression are 
often diagnosed later than women, and sometimes, diagnosis of depression in men is missed  
entirely (37, 38). Diagnostic bias has been noted in autoimmune diseases such as systemic lupus 
erythematosus, which is considered a genetic disease of women (39). A greater delay in 
diagnosis and treatment of the disease is often seen in men who present with similar symptoms 
as women. Consequently, men with the disease end up with worsened outcomes and more 
physiological damage than women (40). 
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In recent years, pulmonary researchers have begun to explore the impact gender may 
have on the diagnosis of airway diseases. Whether women with COPD or asthma receive the 
same medical care for their conditions as men, and whether they are at risk of different outcomes 
as a result, is unknown. 
 The burden of COPD in women is increasing quickly (41). COPD is now responsible for 
more deaths in women than many cancers (41). Epidemiological studies conducted in USA and 
Denmark have shown an increase in COPD deaths in women compared to men (42, 43). Studies 
conducted across Italy, Sweden, UK, and the USA have reported similar COPD prevalence in 
men and women (44), while another conducted in Canada reported a higher prevalence of 
COPD in women smokers than in men smokers (8.2% vs 3.5%) (45). A Dutch study reported 
an increase in prevalence of 20.5% for women and a decline of 48.8% for men over the same 
time period (46). A number of factors may contribute to the increasing prevalence of COPD in 
women. There may be increases in smoking rate amongst women, increased use of biomass as 
fuel for cooking in underdeveloped countries, or exposure to occupational risk factors (47).  
Despite these observations, there is often a disregard for COPD as a woman’s healthcare 
issue. One reason for this may be a gender bias that exists in the perception that COPD is a 
disease of older, male, smokers, still influencing clinical decision making. Women may not 
report symptoms like sputum production and cough due to the societal stigma associated with 
them, and that may also lead to delayed diagnosis or misdiagnosis (48). 
In an Epidemiological Study (EPI-SCAN) conducted in Spain, the odds of receiving a 
correct family physician’s diagnosis for  COPD was two times more for men compared to  
women, after adjusting for age, smoking, education level, mMRC dyspnea score and COPD 
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severity (49). After controlling for confounders, Martinez et al. found women with COPD were 
more likely than men to report diagnostic delay (OR=1.66, 95%CI: 1.13-2.25, p=0.01) and 
difficulty in reaching their physicians (OR=2.54, 95%CI: 1.33-4.86, p=0.004) (50). In validated 
vignette questionnaires, primary-care physicians have stated COPD as the most probable 
diagnosis more often for the man as compared to the woman (58% vs 42%, p<0.05) (51), while a 
greater percentage of women than men have been misdiagnosed with asthma (48% vs 32%) (51).  
Although gender bias in diagnosis of OADs is reduced by the use of spirometry, this tool 
remains underused among primary-care physicians. Studies have shown that a large proportion 
of patients diagnosed with COPD have no history of spirometry testing and less than one-third of 
COPD patients undergo spirometry before their first prescription (14). It has been reported that 
referrals for spirometry may be less in women with respiratory symptoms. After adjusting for 
age, pack-years, country and dyspnea scores, the Confronting COPD survey found that women 
were less likely to have had spirometry (aOR=0.84, 95% CI: 0.72-0.98) as compared to men with 
COPD (52). 
Asthma is the second highest differential diagnosis to COPD. Chapman et al. revealed 
that “there is considerable diagnostic confusion between COPD and asthma, the most common 
alternative diagnosis offered by physicians” (51). Dales et al. found that despite no significant 
differences in bronchodilator responsiveness between genders, physician-diagnosed asthma was 
two times higher in women than in men (53). Together, these data suggest that women or men 
with COPD or asthma may be less likely to be diagnosed and subsequently less likely to be 
treated for their condition (41, 50, 53). Gender inequalities in diagnostic processes may impact 
the therapeutic strategies, symptoms and health-related quality of life of patients.  
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1.1.3 Symptoms and Health-related Quality of Life may differ 
Diagnosis of asthma or COPD first starts with the patients reporting their symptoms to 
their physician. Symptoms associated with respiratory diseases can be debilitating, alarming and 
sometimes life-threatening. Depending on the severity of the disease, a patient with asthma or 
COPD may experience some or all of the following symptoms - cough, sputum production, 
dyspnea, fatigue, chest tightness, weight loss and wheezing (1, 2). Comparing responses from 
two groups of patients, authors found that problems such as difficulty breathing, tiredness, 
depression, loneliness, anxiety, financial instability, limited ability to engage in activities, 
difficulty sleeping, stress, boredom and lower health-related quality of life are reported more 
often by people with COPD as compared to patients without the condition (54). Dyspnoea 
(shortness of breath) is the most significant symptom in COPD and the main determinant of 
health-related quality of life, prognosis and disability in people with the disease (55). Dyspnea 
was found to be the most reported symptom in a study of 68 patients with respiratory disease, 
with fatigue being the second most prevalent (56).  
Symptoms of COPD may differ by sex.  Women with COPD are more likely than are 
men to report dyspnea and less likely to report sputum production (52, 57). Women report higher 
degree of dyspnea, despite fewer pack-years and similar degree of pulmonary impairment (52). 
In a Spanish study, women reported less sputum than men but cough, wheezing and dyspnea 
were reported with the same frequency (41). In the PLATINO study on sex-related differences in 
COPD, dyspnea was more common among women with or without COPD (58). Women may 
have worse COPD symptoms than men (52, 57, 58). COPD exacerbations have been reported 
more often in women than men, while comorbidities such as anxiety and depression are also 
more common in women (59, 60). Evidence suggests that women with COPD experience a more 
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impaired health-related quality of life at an earlier age in their lifetime than men with COPD (58, 
60). 
Like COPD, there may be gender differences in the clinical expression of asthma. 
Women with asthma report more symptoms than men. Out of 400 patients interviewed by 
Zillmer et al., the proportion of women who reported troublesome symptoms like cough with 
sputum, chest tightness and shortness of breath, were greater than men (61). Also, the proportion 
of women who reported that their asthma had caused them to feel lack of control over their lives 
and affected the way they felt about themselves, were also greater than men (61). In a separate 
study by mcCallister et al., women were more likely than men to report symptoms such as 
nocturnal awakenings, activity limitation, and shortness of breath, and to feel bothered by their 
cough or triggers, despite having similar overall asthma control as men (62). Women with 
asthma have also reported poorer health-related quality of life than men (63-66). 
The reasons behind gender differences in the clinical expression of OADs could be 
multifactorial. Societal concept of athleticism may cause men to report less dyspnea than women 
(67). Also, social and cultural factors may result in women being less likely to report the 
production of phlegm or sputum (68).  Furthermore, differences in the physiological and 
biological make-up of men and women may influence the expression of the disease (69). 
Moreover, bias in the care given by health care workers could also lead to worse symptoms or 
poorer health-related quality of life for men or women with respiratory diseases (52, 68). 
1.1.4 Management differences 
Management of respiratory conditions involves the use of pharmacological and non-
pharmacological means. The main component of non-pharmacological therapy is pulmonary 
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rehabilitation. Aspects of a rehabilitation program are education (smoking cessation, information 
on COPD or asthma, allergen avoidance, etc.), specific respiratory muscle training, nutritional 
intervention, exercise training and motivational coaching. The aim of non- pharmacological 
management is to improve  patients’ quality of life, reduce symptoms and number of 
hospitalizations, improve exercise tolerance, reduce anxiety and depression, and increase 
survival (1, 2, 70).  
Pharmacological management of respiratory conditions involves the use of medications 
to treat the conditions.  There are currently no medications to cure COPD or fully reverse the 
extent of the damage. Pharmacotherapy is aimed at preventing and controlling symptoms, 
reducing frequency and severity of exacerbations, slowing disease progression, improving health 
status and reducing mortality (1, 2, 70). Like COPD, asthma has no cure. However, airway 
narrowing in asthma can be fully reversed by medications, but only temporarily. Asthma 
pharmacotherapy is aimed at achieving and maintaining clinical control (1).  
 Authors of clinical guidelines recommend that pharmacological and non-
pharmacological therapies be used together to manage patients with COPD or asthma (1, 2). For 
both asthma and COPD, pharmacological therapy employs the following medications: short-
acting beta-agonists (SABA),  long-acting beta-agonists (LABA), anticholinergics, 
corticosteroids and combination therapy (1, 2). While the same medications are used for both 
conditions, answers to the questions of ‘when, how and why’ these medications are used may 
differ. For instance, inhaled corticosteroids are advantageous in both conditions, but are used at 
different stages of the diseases. In asthma, inhaled steroids are used in the early stages of the 
disease. However in COPD, inhaled steroids are added after the patient has developed severe 
acute COPD with multiple exacerbations. Also, while LABAs are conveniently used for the 
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initial COPD treatment, LABAs are not used in asthma until the patient has gotten to the 
moderate persistent stage of the disease (1, 2).  
Authors of the Global Initiative for Asthma (GINA) and Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) recommend the same therapy for both sexes (1, 2). 
Nonetheless, it is unclear whether the implementation of these guidelines differs between men 
and women in real practice. 
 Differential treatment of chronic diseases, on the basis of gender, has been discussed in 
many studies.  For instance, in the cardiovascular literature, out of those patients who were ideal 
candidates for an aspirin therapy, women were less likely than men to be given this therapy 
within 24 hours of hospitalization (aRR=0.94, 95%CI: 0.92-0.95) (25). Similarly, in two 
different studies, women were less likely to receive antiplatelet, β-blocker, or lipid-lowering 
therapies for peripheral artery diseases (71, 72). An unequivocal bias in management was 
established in a study by Abuful et al. where a 2-part study was designed to compare physicians’ 
attitudes with their actual clinical practice in preventive therapy for coronary artery disease 
(CAD) (73).  In the Attitude study, hypothetical case scenarios of a man and woman with the 
same age, identical clinical and laboratory data, and mild coronary atherosclerosis on 
angiography were presented to participating physicians. In the actual clinical study, authors 
examined lipoprotein levels and prescriptions for lipid-lowering medications from medical 
records of men and women with angiographic evidence of CAD. The Attitude study revealed that 
despite the similar clinical patient data, physicians considered the male patient to be at higher 
risk and therefore prescribed aspirin (91% vs 77%, p<0.01) and lipid-lowering medications (67% 
vs 54%, p<0.07) more often for the man. In the Actual clinical practice study, chart reviews 
showed that 77% of males were prescribed a lipid-lowering medication compared to 47% of 
 11 
females (p<0.001). The authors concluded that they found clear evidence of gender bias in both 
the attitude and the actual clinical practice of prevention therapies for patients with CAD (73).  
Similarly in the pulmonary literature, women have been less likely than men to get a 
prescription for nicotine patches but have been more likely to receive advice to quit smoking (52, 
74). Dales et al. found that women were less likely than men to be prescribed medications if 
COPD was mild or moderate, but were as likely as men to be on respiratory medications if 
COPD was severe (53). Despite having similar symptoms and disease severity, women have 
been reported to be less likely than men to be on anticholinergic agents (57). Two studies found 
no difference in prescription for corticosteroids between genders (52, 75). Also, after controlling 
for potential confounders,  men have been reported to be more likely than women to be on dry 
powder inhalers and to have “appropriate inhaler combinations” (75, 76). 
1.2 Rationale and justification 
Unlike the extensive work done in cardiovascular diseases, evidence of gender disparities 
in the diagnosis of OADs is still in the elementary stages. A bias in diagnosis may result in 
delayed or misdiagnosis, potentially leading to suboptimal treatment and worsened outcomes for 
men or women. Despite the growing evidence supporting a potential bias in COPD diagnosis, 
there have been limited research studies and evidence is inconclusive. While a number of 
narrative reviews (14, 48, 68) exist on this topic, no systematic review has been conducted as a 
more objective, less-biased method to synthesize existing evidence and draw appropriate 
conclusions.   
Research in other jurisdictions has shown that a bias may exist in the diagnosis of COPD 
(41, 49, 77). However, very few studies on gender disparities in care have been conducted in 
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North America. In a Canadian study on physicians’ attitudes towards men and women, primary-
care physicians were found to be more likely to diagnose COPD in men as compared to women, 
even though men and women may present with the same history, physical findings and disease 
severity (51). That study could, however, be limited, as the validated vignette questionnaires may 
not represent actual clinical practice. Moreover, the study was conducted over a decade ago and 
has not been updated to see if the trend exists in more recent years.  Again, while some work has 
been done in COPD, gender diagnostic bias has been rarely investigated in asthma. The 
population considered in a study by Leynaert et al. was patients with asthma-like symptoms and 
bronchial hyper- responsiveness (78). Thus, this may be the first project to dissect gender 
diagnostic bias in patients with objectively known asthma. 
1.3 Purpose 
The purpose of this project is to compare family physician’s diagnostic processes 
between men and women who meet objective criteria for COPD or asthma. We also 
hypothesized that gender inequalities in diagnostic processes may impact the therapeutic 
strategies, symptoms and health-related quality of life of patients. Therefore, as a secondary 
objective, we explored differences in cardinal symptoms, health-related quality of life and 
medication prescription patterns of men and women with COPD or asthma. To achieve this 
purpose, we first conducted a systematic review and meta-analysis for COPD. However, a 
systematic review and meta-analysis was not conducted for asthma as a literature search 
indicated lack of relevant studies. We also performed a secondary data analysis for COPD and 
asthma.  
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1.4 Significance 
Women, have been reported to have poorer outcomes in OADs than men in terms of 
mortality rates, hospitalization frequency, emergency visits, dyspnea symptoms and health-
related quality of life.  The rapid rise in prevalence and worsened outcomes in women as 
compared to men with asthma/COPD could be because of gender differences in diagnosis of the 
disease. Exploring and assessing the gender disparities in diagnosis of obstructive airway 
diseases may provide valuable information to develop hypotheses as to why these differences 
might exist, to reduce these disparities, and to identify areas for future research. The end goal is 
to achieve improved interventions and outcomes for both men and women. 
1.5 Program of research for thesis  
This thesis is comprised of two studies aimed at addressing the gaps, limitations and 
current knowledge surrounding gender diagnostic bias. Firstly, a systematic review and meta-
analysis was conducted to summarize and synthesize existing literature on gender bias in COPD 
diagnosis, and to obtain a single, more precise estimate of the extent of bias, using meta-analysis. 
(Research study #1) 
A secondary analysis of data obtained from the Epidemiology of Shortness of Breath 
(EpiSOB) study, conducted in Edmonton and Saskatchewan, was then conducted to explore 
gender disparities in a Canadian setting, and to address diagnostic, symptoms and treatment gaps 
identified by the review. (Research study #2) 
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1.6 Research questions 
In patients with COPD, does being a man as compared to being a woman influence the 
diagnosis of the condition? 
In patients with asthma, does being a man as compared to being a woman influence the 
diagnosis of the condition? 
1.7 Specific Research Objectives 
1.7.1 Primary objectives (diagnostic outcomes): 
i. To compare rate of physician-diagnosed COPD between men and women who meet 
spirometry criteria for COPD (Research study #1 and Research study #2) 
ii. To compare rate of misdiagnosis between men and women who meet spirometry 
criteria for COPD (Research study #2) 
iii. To compare referral rate to a specialist between men and women (Research study #2) 
iv. To compare referral rate for spirometry between men and women (Research study #1 
and Research study #2) 
v. To compare referral rate for chest x-ray between men and women (Research study 
#2) 
vi. To compare referral rate for methacholine test between men and women (Research 
study #2) 
vii. Repeat the above for patients with asthma (Research study #2) 
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1.7.2 Secondary objectives 
viii. To compare medication prescription patterns for men and women (Research study #1 
and Research study #2) 
ix. To compare symptoms of men to those of women (Research study #1 and Research 
study #2) 
 
x.  To compare health-related quality of life of men to those of women (Research study 
#1 and Research study #2) 
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2.1 Abstract 
Background and objective:  
Recent studies have reported gender bias in the diagnosis of chronic diseases including 
those of cardio-pulmonary origin. A comprehensive systematic review has not been conducted to 
synthesize the existing evidence for chronic obstructive airway diseases. In this review, we 
studied the differences in the diagnosis of chronic obstructive pulmonary diseases (COPD) 
among men and women. As a secondary objective, we explored differences in medication 
prescription patterns, symptoms and health-related quality of life of men and women with 
COPD.  
Methods:  
We followed standard methods for conducting a systematic review and meta-analysis, as 
outlined in the Cochrane handbook for systematic reviews of interventions. An exhaustive 
literature search was conducted using 3 electronic databases including MEDLINE (PubMed), 
EMBASE and CINAHL. Appropriate studies related to the research question were identified, 
screened and selected.  Two reviewers independently assessed the selected articles for relevance 
and methodological quality. Relevant articles were selected for descriptive synthesis and 
quantitative synthesis. The Inverse Variance (IV) random effect model was used for analysis.  
Heterogeneity between studies was explored and publication bias was checked visually and 
quantitatively. 
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Results:  
Of the 967 studies retrieved, 28 were included in the descriptive synthesis and 18 studies 
in the quantitative synthesis (meta-analysis). Gender bias in COPD diagnosis may exist, as men 
were more likely to be correctly diagnosed with COPD by primary care physicians (OR=2.09, 
95% CI: 1.44-3.05), and women with respiratory symptoms were less likely to be referred for 
spirometry (OR=0.86, 95% CI: 0.77-0.96). Also, men with COPD had a better health-related 
quality of life than women based on the SGRQ scores (Standardized mean difference= -0.19, 
95% CI: -0.29 to -0.09). 
Conclusion:  
There exist gender differences in diagnosis of COPD and referral for spirometry. Women 
with COPD are more likely to report lower health-related quality of life than men. There was 
insufficient evidence to support or refute gender bias in physicians’ prescription patterns for 
COPD medications. 
Keywords:  
COPD, gender differences, gender bias, primary-care physicians, family physicians, 
meta-analysis, systematic review.  
Word Count: 325 
  
 24 
2.2 Introduction 
Gender inequalities in healthcare services remain a topic for discussion. Gender biases 
may result in unequal medical practices or outcomes between men and women. Gender 
differences in referral for diagnostic tests have been identified in chronic heart disease, which 
has been considered a “male disease”, putting women at risk of underdiagnoses (1, 2). 
In recent years, pulmonary researchers have begun to explore the impact gender may 
have on the diagnosis of airway diseases. COPD has historically been considered to be an illness 
of men, due to the perceived higher smoking rates in men as compared to women (3). Increasing 
evidence, however, suggests that many women are now smoking, and more and more women are 
employed in industries where air pollution is pronounced (4). 
Epidemiological studies conducted in USA and Denmark have shown an increase in 
COPD deaths in women compared to men (5, 6). In  Canada, COPD prevalence was found to be 
8.2% in women who smoke compared to 3.5% in men who smoke (7). Despite these 
observations, evidence suggests that the diagnosis of COPD is made much more often, and more 
correctly in men (8, 9).  Conversely, women are more likely to be diagnosed with asthma when 
the correct diagnosis is COPD, due to the perception that COPD is not a woman’s disease (8-10). 
An objective measure of lung function, spirometry, has proven to be a good measure to 
confirm COPD or asthma diagnosis and to differentiate between the two diseases (11, 12). 
Authors of clinical guidelines highly recommend using spirometry before diagnosing COPD (11, 
12). Unfortunately, it has been reported that very few physicians make use of this tool in their 
investigation of chronic respiratory symptoms, with women being less likely to be referred for 
spirometry (8, 9, 13). Gender bias in diagnosis may impact treatment and health outcomes. A 
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number of epidemiological studies are available that suggest that diagnostic efforts are lower in 
women with COPD (8, 9, 13-15). However, a comprehensive systematic review has not been 
conducted to synthesize the existing evidence and draw appropriate conclusions.  
The aim of this study is to systematically review, summarize and synthesize existing 
literature on gender bias in COPD diagnosis, and to simultaneously combine estimates from 
eligible studies (based on comparable outcomes and population), using meta-analysis, to obtain a 
single, more precise estimate of the extent of bias. 
This review addresses the following question:  In patients with COPD, does being a man 
as compared to being a woman influence the diagnosis of the condition? As a secondary 
objective, we explored cardinal symptoms, health-related quality of life and medication 
prescription patterns of men and women with COPD. 
2.3 Methods  
We followed standard methods for conducting a systematic review and meta-analysis, as 
outlined in the Cochrane handbook for systematic reviews of interventions (16). The review was 
also conducted and reported on the basis of the Preferred Reporting Item for Systematic Review 
and Meta-analysis (PRISMA) checklist (17) and the checklist of Meta-analysis of Observational 
Studies in Epidemiology (MOOSE) (18). 
2.3.1 Outcome measures 
Our primary outcomes were the rate of physician-diagnosed COPD and referral for 
spirometry in men and women who meet objective criteria for COPD. We defined physician-
diagnosed COPD as patient self-reported diagnosis of COPD from a primary-care physician, or a 
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primary-care physician’s diagnosis based on validated case scenarios. Also, referral for 
spirometry was defined as the proportion of patients that had undergone spirometry before 
diagnosis, or up to one year after diagnosis of COPD. Our secondary outcomes were differences 
in medication prescription patterns, cardinal COPD symptoms (dyspnea, cough and sputum 
production) and health-related quality of life. 
2.3.2 Literature search 
We conducted the literature search using MEDLINE (PubMed), EMBASE and CINAHL, 
including articles published from inception of the databases to December 2017. We maximized 
retrieval of searches by using MeSH terms and keywords, and a combination of the two. The 
MeSH terms used were “Pulmonary Disease”, “Chronic Obstructive”, and “Sexism”.  Keywords 
used were “COPD”, “chronic obstructive pulmonary disease”, “gender difference”, “gender 
factor”, “gender bias” and “sex bias”. 
  Reference lists of eligible articles as well as reference lists of narrative reviews on gender 
differences in COPD were hand searched to identify additional studies. We also contacted some 
study authors to obtain additional information on studies that were relevant. Our literature search 
strategy focused on studies conducted in humans, with no restriction on language. The intensive 
search started on the 10th of September 2017 and the last search was completed on December 
15, 2017. The final search string used for searching studies in PubMed, Embase and CINAHL is 
shown in appendix A. 
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2.3.3 Study selection  
Two authors (LA, MAB) independently screened titles and abstracts of articles yielded 
by the initial database search. Full text articles of relevant studies were retrieved and reviewed by 
two authors (LA, MAB) to determine eligibility.  
The inclusion criteria captured retrospective cohort studies, cross-sectional studies, case-
control and matched case-series studies that compared the differences between men and women 
in terms of diagnosis, medication prescribing, symptoms or health-related quality of life. Studies 
were included if: (1) diagnostic outcomes were stated as physician-diagnosed COPD, correct 
diagnosis of COPD, prior physician diagnosis of COPD and referral for spirometry or anything 
similar,   (2) health-related quality of life was assessed using a validated tool, (3) at least one 
cardinal COPD symptom was assessed and (4) medication prescription pattern was defined as 
the likelihood of the man or woman being prescribed with COPD medications (e.g. short-acting 
beta agonists, long acting beta agonists, anticholinergics, etc.). 
We excluded studies that only measured COPD prevalence by gender, rather than correct 
physician diagnosis by gender.  Interventional studies such as clinical trials were excluded since 
we were only interested in medication prescription patterns of physicians, rather than the 
implementation of any intervention on drug prescription for COPD patients. We also excluded 
commentaries, narrative reviews, case reports and editorials. Studies were included in the 
quantitative synthesis (meta-analysis) if (1) they investigated the association between gender and 
physician-diagnosed COPD, referral for spirometry, symptoms, health-related quality of life and 
treatment, (2) if they also used odds ratio (OR) or relative risks (RR) with corresponding 95% 
confidence intervals (CI) as measures of associations. Also studies were included if summary 
measures of continuous or scale outcomes were reported as mean difference and interquartile 
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range (IQR). Any disagreement in study selection was resolved by discussion, while adhering 
strictly to the inclusion/exclusion criteria.  
2.3.4 Data extraction  
We developed a standardized form to guide in the data extraction process. The following 
data were extracted: author’s first name and year of publication, country of study, characteristics 
of the population sampled, number of men and women compared, and outcomes such as 
physician-diagnosed COPD, referral for spirometry, cardinal COPD symptoms (cough, dyspnea 
and sputum production), health-related quality of life scores and adjusted confounders. Study 
results are summarized in Tables 2.1 to 2.4.  
2.3.5 Quality Assessment 
A quality assessment of articles that passed the inclusion/exclusion criteria was 
undertaken using the US Preventive Services Task Force (USPSTF) Quality Rating Criteria 
assessment of research bias for cohort and case-control studies (19). Two authors (LA, MAB) 
independently assessed the methodological quality and risk of bias of each study and graded each 
study as good, fair or poor using USPSTF criteria.  Names of authors, study titles and journal of 
publication were blacked out by an independent reviewer to ensure a fair assessment free from 
assessor bias. Any disagreements between authors during assessment were resolved by 
discussion until a consensus was reached.  
2.3.6 Statistical Analysis 
Meta-analysis was done using the Review Manager (RevMan) vs. 5.3 software provided 
by the Cochrane Collaboration, and Comprehensive Meta-analysis (CMA) software. The 
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weighted mean difference (WMD) or standardized mean difference (SMD) with their 
corresponding 95% confidence interval (CI) was calculated for continuous outcomes such as 
health-related quality of life scores. Estimates that were reported in median (and IQR) were 
converted to mean (and SD) before analysis. To facilitate comparability, the directions of 
associations were reversed if lower scores indicated more impairment. For example, health-
related quality of life scales that were in opposite direction to St. George’s respiratory 
questionnaire (SGRQ) scale were reversed to the same direction by multiplying the mean values 
from that set of studies by −1 (20).  Also, the oxygen cost diagram (OCD) dyspnea scale was 
reversed to the same direction as the modified medical research council (MMRC) dyspnea scale.  
For dichotomous outcomes (e.g. Physician-diagnosed COPD or referral for spirometry), 
estimates of association measures such as odds ratio (OR) were calculated. Heterogeneity and 
homogeneity were assessed using Cochran (Q-statistics) and I2, and a random effects model was 
employed due to suspected heterogeneity.  Publication bias was visually examined using a funnel 
plot. Egger’s and Begg’s tests were conducted to test for funnel plot asymmetry, as a quantitative 
assessment of publication bias. Sensitivity analysis was conducted to assess the influence of 
outliers on results. In cases where meta-analysis could not be performed, the data were 
summarized descriptively.  
2.4 Results 
2.4.1 Systematic search 
Our initial broad database search identified 967 publications (PubMed=157, 
Embase=365, Cinahl=445). Scanning through the reference lists of narrative reviews yielded an 
additional 10 articles. 33 of these publications were identified as duplicates and excluded, with a 
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total of 944 articles remaining. The titles and abstracts of 944 articles were screened for 
relevance by two reviewers (LA, MAB), of which 873 articles were excluded for improper study 
outcomes.  The full-texts of the remaining 71 articles, published in English and Spanish (one 
article) were retrieved for further assessment. After assessing all 71 full text articles, 43 articles 
were excluded because they did not meet the inclusion/exclusion criteria, leaving a remaining 
number of 28 articles for the review (See Figure 2.1).  
2.4.2 Description of included studies  
The 28 selected papers were made up of 5 retrospective cohort studies, 20 cross-sectional 
studies, 1 case-control and 2 matched case-series studies. The publication years of the studies 
ranged from 1999 to 2017. The studies were conducted in the USA, Denmark, Spain, Canada, 
France, UK, Japan, Uruguay, Italy, Brazil and Norway. Important confounders such as age, 
smoking status, education level, level of dyspnea, COPD severity, and comorbidities were 
adjusted for by most studies. Most studies reported effect size as odds ratios (ORs) or relative 
risk (RR) for dichotomous outcomes and mean difference (SD), or median (IQR) for continuous 
outcomes. Some others reported study results using frequency tables. Thus, out of 28 studies, 18 
qualified for meta-analysis based on appropriately reported effect estimate, comparable 
population and comparable outcomes.          
COPD was defined by most studies as FEV1/FVC < 0.7 after the use of a bronchodilator, 
while few others also used the criterion FEV1/FVC < lower limit of normal (LLN). The outcome 
“physician-diagnosed COPD” was defined by four studies as a self-reported diagnosis of COPD, 
based on participants’ response to the questionnaire “Has your family physician ever told you 
that you have COPD?”  The reported diagnosis of COPD was considered correct if it matched 
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the spirometric COPD criteria (post bronchodilator FEV1/FVC < 0.7 or FEV1/FVC < LLN) used 
by the authors and experts at the time of the study visit. The proportion of correct diagnosis was 
compared between men and women.  
Three other studies assessed “physician-diagnosed COPD” using validated vignette 
questionnaires (8, 9, 21). In those studies, hypothetical case scenarios of a man and woman with 
similar symptoms, disease severity and similar information on patient history and physical 
findings were presented to participating physicians. Characteristics presented were typical of a 
person with COPD. Physicians were then asked to state the most probable diagnosis based on the 
information provided them, and then choose the diagnostic study(s) they would recommend for 
the man versus the woman, like they would in real practice.  
Referral for spirometry was assessed by studies as the proportion of patients who had 
undergone at least one spirometry in the period of 6 months before their first prescription or 
diagnosis to 12 months after their first prescription or diagnosis of COPD. This data was 
extracted from patient registers by two studies while two other studies used recall.  
Studies that compared “symptoms” and “health-related quality of life” between men and 
women randomly sampled COPD patients from clinics. The 3 main symptoms of COPD 
(dyspnoea, cough and sputum production) were assessed using the following clinically validated 
questionnaires: modified medical research council (mMRC) dyspnea scale and chronic 
respiratory questionnaire (CRQ) dyspnea domain. For health-related quality of life, 
questionnaires used were St. George’s respiratory questionnaire (SGRQ), chronic respiratory 
questionnaire (CRQ), euroqol-5D (EQ-5D) scale, short form 12 (SF-12) questionnaire and short 
form 36 (SF-36) scales.  For “medication prescription patterns by gender”, medical records of 
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patients were screened for data in three studies, while patient self-report data were used in two 
studies.  
2.4.3 Quality assessment 
The quality score for each paper is summarized in Tables 2.5 and 2.6. Overall, the articles 
chosen were of “fair” quality (i.e. 13 good, 14 fair and 1 poor). Across all studies, sampling was 
done randomly. The possibility of selection bias was reduced by incorporating matching into the 
study design of two studies, while 24 studies controlled for this bias at the data analysis stage by 
adjusting for potential confounders (e.g. age, smoking status, educational level, level of dyspnea, 
COPD severity, and comorbidities). Recall bias may however be high for studies in which 
participants self-reported “physician-diagnosed COPD”.  A satisfactory response rate was seen 
across studies. Only one out of the 28 papers was given an overall “poor” assessment due to poor 
methodology, with lack of appropriate attention to confounders. This study was therefore 
excluded from the meta-analysis (9). However, “fair” quality articles were included in the meta-
analysis because they satisfied key bias domains (response rate, adjustment for potential 
confounders, and all important outcomes considered) relevant to our outcomes (22). In all, 18 
studies were included in the meta-analysis. 
Insert (Tables 2.5 and 2.6 here) 
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Figure 2.1 PRISMA flow diagram 
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2.4.4 Descriptive analysis of outcomes  
2.4.4.1 Physician-diagnosed COPD 
Seven studies compared the likelihood of a physician-diagnosed COPD in men as 
compared to women (8, 9, 21, 23-26). Four studies, using odd ratios and relative risks as 
measures of association, found that men were more likely to have had a correct diagnosis of 
COPD as compared to women after controlling for potential confounders such as age, smoking 
history, education level, mMRC dyspnea, COPD severity and comorbidities. Three studies 
compared physician diagnosis behaviour among men and women using frequency measures (9, 
25, 26). Chapman et al. found that men (58%) were more likely to be diagnosed with COPD than 
women (42%) with p<0.05 (9). Martinez et al. found that women were more likely to report 
COPD diagnostic delay (OR=1.66, 95%CI: 1.13-2.45, p=0.01) (25), while Roberts et al.  
reported that more men than women had a correct COPD diagnosis (87.5% vs 73.9%, p=0.021) 
(26). Meta-analysis was possible for four out of these seven studies (8, 21, 23, 24).  
2.4.4.2 Referral for spirometry 
Four studies reported on spirometry use and found that women were less likely to be 
referred for spirometry, after adjusting for potential confounders namely age, pack-years of 
smoking, country, dyspnea severity, sex, race, comorbidity and number of pulmonary 
medications received. Specifically, Watson et al found women were 0.84 times less likely than 
men to be referred for spirometry (OR=0.84, 95%CI: 0.72-0.98) (13). Shawn et al found women 
were 0.96 times less likely than men to be referred for spirometry (OR=0.96, 95%CI: 0.82-1.12) 
(14). Delgado et al found women were 0.43 times less likely than men to be referred for 
spirometry (OR=0.43, 95%CI: 0.23-0.81) (21) and Koefoed et al found women were 0.86 times 
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less likely than men to be referred for spirometry (OR=0.86, 95%CI:0.82-0.90) (27). Meta-
analysis was possible for all four studies (13, 14, 21, 27).  
2.4.4.3 Medication prescription patterns 
Physician behavior on prescribing medications for men and women was explored by five 
studies. Rinne et al. reported that women were less likely than men to be prescribed short-acting 
beta agonists (SABA) (OR=0.83, 95%CI: 0.72-0.95), short acting muscarinic antagonists 
(SAMA) (OR=0.76, 95%CI: 0.67-0.86), long-acting beta agonists (LABA) (OR=0.87, 95%CI: 
0.77-0.99) and long acting muscarinic antagonists (LAMA) (OR=0.74, 95%CI: 0.63-0.87) (28). 
However, there was no difference in inhaled corticosteroids (ICS) (OR=0.96, 95%CI: 0.85-1.09) 
and oral steroids (OR=1.01, 95%CI: 0.88-1.16) use between genders. Also, women received 
fewer “appropriate inhaler combinations” (OR=0.83, 95%CI: 0.74-0.93) and had more 
“inappropriate drug combinations” (OR=1.33, 95%CI: 1.17-1.51) compared to men (28). Watson 
et al. found no difference between genders in ICS use (OR=1.01, 95%CI: 0.84-1.21) (13). 
Sherman et al. reported that women were less likely to receive a prescription for nicotine patches 
or gum (OR=0.5, 95%CI: 0.3–0.9) (29).  In a study by Carrasco-Garrido et al., men received a 
larger number of drugs for COPD than women, with a greater frequency of LABA (9.8% vs 
7.9%, p<0.05), anticholinergic drugs (85.6% vs 82.4%, p<0.05) and theophyllines (13.2% vs 
7.6%, p<0.05). However, no gender differences were recorded in the frequency of prescription of 
inhaled corticosteroids (22.1% vs 22.2%, p>0.05) and oral corticosteroids (4.4% vs 5.3%, 
p>0.05) (30).   
Data from studies suggest that women may be less likely to receive some medical 
treatments. However, not enough studies have been done on each drug class, as different studies 
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reported prescription behaviour on different drug classes. We were able to quantitatively 
synthesize data on only one drug class (ICS) obtained from only 2 studies (13, 28).  
2.4.4.4 Symptoms  
Cough, dyspnoea, and sputum production are the major symptoms that patients with 
COPD complain of (31). As a secondary objective, we explored differences between men and 
women in their expression of COPD disease. Dyspnoea is the most significant symptom in 
COPD and the main determinant of quality of life, prognosis and disability in people with the 
disease (32). Almost all studies reported that women experience worse dyspnea than men. Two 
studies (13, 33) reported effect estimates as odds ratio, and were combined in a separate meta-
analysis from those that reported dyspnoea scores (34-36). Data for cough and sputum 
production was mostly reported as frequencies, thus, it was not possible to summarize them 
quantitatively. One study, using odds ratio, reported that women were less likely to report 
sputum production (OR=0.84, 95%CI: 0.72-0.98) but were as likely as men to report cough 
(OR=1.08, 95%CI: 0.92-1.27) (13). Naberan et al. reported that sputum production was more 
frequent among men (73.3% vs 64.7%, p<0.001) but frequency of cough did not differ between 
genders (80% vs 77.6%, p=0.75) (37). Raherison et al. however found no significant differences 
between genders in frequency of cough (men, 75.6% vs women, 78.5% p=ns) or production of 
sputum (men, 62% vs women, 64.2% p=ns) (38). Available data on sputum production appeared 
inconsistent across studies. For instance, while two studies reported a higher frequency of 
sputum production in men than in women (13, 37), one study found no significant difference 
between genders (38). Available data however suggested that women may report cough with the 
same frequency as men (13, 37, 38).  
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2.4.4.5 Health-related Quality of life 
Almost all studies found women to have lower health-related quality of life than men. 
Two studies (34, 39) however found no significant differences between men and women in 
health-related quality of life scores. Specifically, Roche et al found no significant difference 
between men and women in SGRQ health-related quality of life scores (median, IQR: m 43, 30-
59 vs w 46, 32-60, p=0.35] (34) and Skumlien et al also found no significant difference in SGRQ 
health-related quality of life scores (mean±SD: 56.5±16 vs 58.7±14.1) (39). Nine out of 13 
papers on health-related quality of life were quantitatively summarized (15, 34, 37, 39-42) 
Insert (Table 2.1 to 2.4 here) 
2.4.5 Results of Meta-analysis 
Four studies were synthesized with the outcome “physician-diagnosed COPD”. The 
forest plot below shows an inverse variance (IV) random effect model with pooled odds ratio of 
2.09 and 95% confidence interval of 2.10 to 7.21 and p-value of 0.0001. This means that men are 
2.09 times more likely to have a COPD diagnosis by their primary physicians as compared to 
women, even though both may have COPD based on spirometry criteria. This effect estimate is 
however compromised since substantial heterogeneity exists with I2=61% and Chi2=7.66, with 
df=3, p=0.05. We did not subgroup the four studies because of the small number of studies 
included.   
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Figure 2.2 Forest Plot assessing whether men are more likely than women to be diagnosed with 
COPD 
Four studies were synthesized with the outcome of “percent referral for spirometry.” 
Results from the meta-analysis as shown in the forest plot in Figure 2.3 shows an overall 
summary effect odds ratio with 95% confidence interval as 0.86 (0.77,0.96). Hence women are 
significantly less likely to be referred for spirometry compared to men. The pooled effect 
estimate is acceptable since heterogeneity was moderate, I2=54%. 
 
Figure 2.3 Forest Plot assessing whether women are less likely than men to be referred for 
spirometry 
Two studies were synthesized with the outcome of prescription of ICS.  The combined 
effect of 0.97(95%CI: 0.88-1.08) shows that although women were slightly less likely to be 
prescribed with ICS than men, the association was not statistically significant (Figure 2.4).  
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Figure 2.4 Forest Plot assessing whether women are less likely to be prescribed inhaled 
corticosteroids. (ICS) 
Figures 2.5 and 2.6 indicate that women are significantly more likely to have worse 
dyspnoea than men. However, the small number of studies makes this inconclusive. The analyses 
presented in Figure 2.5 are those studies that reported only odds ratios (ORs) and that presented 
in Figure 2.6 are studies that reported mean difference (SMD).  
 
Figure 2.5 Forest Plot assessing whether women are more likely than men to have dyspnoea 
(dichotomous) 
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Figure 2.6 Forest Plot assessing whether women have worse dyspnoea than men (in terms of 
scores) 
Nine of the studies measured health related quality of life (HRQOL) using SGRQ, ED-
5Q, AQ2O and SF-12 scores. The pooled standard mean difference of -0.25 (95%CI: -0.34 to       
-0.17) indicates a lower score on health related quality of life, and the lower the score, the better 
the health-related quality of life. Thus, the pooled effect standardized mean difference of -0.25(p 
<0.00001) as shown in the forest plot in Figure 2.7 indicates that men had better health-related 
quality of life than women with COPD. However there exist substantial heterogeneity which 
suggest that the results are not similar from study to study (I2=83%, p<0.00001). 
 
 
Figure 2.7 Forest Plot assessing whether women have worse health-related quality of life than 
men (in terms of scores) 
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2.4.5.1 Subgroup analysis of Health-related quality of life (HRQoL) 
Heterogeneity can be explored based on clinical or methodological differences across 
studies, for example, differences in outcome assessments (20). Thus, to identify the source of 
heterogeneity among the included studies, studies which measured health-related quality of life 
with SGRQ were classified as one group, while the remaining studies with other health-related 
quality of life measures, namely ED-5Q, AQ2O and SF-12 were classified into another 
subgroup. The first subgroup recorded an I2 of 32% with p-value of 0.21, meaning the observed 
combined effect is not significantly influenced by heterogeneity. The second subgroup recorded 
an I2 of 88%, meaning the observed combined effect is significantly influenced by heterogeneity.  
The heterogeneity is likely due to the differences in the measured instruments/measures used 
with different domains. 
 
Figure 2.8 Forest Plot assessing whether women have worse health-related quality of life than 
men (subgroup analysis by different scales) 
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2.4.5.2 Publication bias 
The visual assessment and detection of publication bias was performed using funnel plot. 
Publication bias check for forest plots in Figures 2.4, 2.5 and 2.6 were not performed due to the 
smaller number of the studies (3 or 2 studies) included at the synthesis stage. 
By inspecting Figure 2.9, there seems to be some funnel plot asymmetry indicating a 
possible publication bias in the studies that assessed men as having a higher likelihood of COPD 
diagnosis than women. This means that it is possible that only studies with significant findings 
have been published for this outcome, while similar studies with non-significant results remain 
unpublished (43). Thus, a meta-analysis of those published studies may lead to an overestimation 
of the combined effect (43). 
 
Figure 2.9 Publication bias check for studies assessing whether men are more likely than women 
to be diagnosed with COPD 
Similarly, visual inspection of Figure 2.10 clearly demonstrates a possible publication 
bias among the 4 studies that measured referral rate for spirometry, implying a possible 
overestimation of the overall effect estimate for this outcome. 
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Figure 2.10 Publication bias check for studies assessing whether women are less likely than men 
to be referred for spirometry. 
The funnel plot of studies that assessed patients’ health-related quality of life seems to be 
symmetric indicating a low likelihood of publication bias in the studies selected for the synthesis 
(Figure 2.11). However, results from the Beggs (one tailed p-value for the Beggs and Mazumdar 
rank correlation test = 0.14857) and Eggers (one-tailed p-value = 0.40016) test confirm that there 
is no significant publication bias of this outcome (Table 2.7).  
 
Figure 2.11 Publication bias check for studies assessing whether women have lower health-
related quality of life than men (in terms of scores) 
Insert (Table 2.7 here) 
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2.4.5.3 Sensitivity analysis  
A sensitivity analysis was performed on the forest plot that assessed whether women 
were less likely to be referred for spirometry than men, to test the effect of the outlier on the 
results. By removing the study conducted by Delgado (2016) with a wider confidence interval, 
studies in the reduced forest plot were homogeneous with I2=0%, p=0.38 with no significant 
heterogeneity (see appendix). Therefore, we may conclude that women are significantly less 
likely to be referred for spirometry than men (OR= 0.87, 95% CI: 0.83-0.90). 
(See Appendix A). 
2.5 Discussion 
The findings from this review show a statistically significant association between male 
gender and a previous diagnosis of COPD and referral for spirometry. Female gender was 
associated with more dyspnea and lower health-related quality of life. There was no significant 
difference between men and women in the use of inhaled corticosteroids (ICS). 
COPD has been perceived as a typical disease of an elderly man, plagued by cough and 
breathlessness after many years of cigarette smoking (3). Some epidemiological studies have 
reported growing prevalence of COPD in women (5, 6, 23). Our findings suggest that COPD 
underdiagnoses may be high in women, with men being about two times more likely to be 
diagnosed with the condition after adjusting for potential confounders. However, due to 
considerable heterogeneity among studies (I2>60%), this finding remains inconclusive. The exact 
reasons for a possible biased diagnosis remain unclear. One of the underlying reasons may be the 
inaccurate, outdated perception of COPD being a male-dominated disease, still affecting clinical 
decision making. Also, there could be lack of awareness of symptoms amongst women (10). 
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Additionally, women often feel embarrassed by symptoms such as cough and sputum production, 
due to the stigma associated with them (popularly called the smoker’s cough), and may not 
report it, resulting in delayed diagnosis or mis-diagnosis (10). 
Even though spirometry forms an integral part of COPD diagnosis, this tool remains 
underutilized among primary care physicians. Studies have shown that a large proportion of 
patients diagnosed with COPD have no history of spirometry testing and only one-third of COPD 
patients undergo spirometry before their first prescription (44). Our findings further suggest that 
women are less likely to be referred for spirometry. Interestingly, a flawed diagnostic process 
may affect the health outcomes of COPD patients. Previous narrative reviews have reported that 
women experience worse COPD symptoms than men (45, 46). Results of this study show that 
women with COPD have a lower health-related quality of life, after adjusting for age, degree of 
airflow obstruction, pack-years of smoking, FEV1 and dyspnoea severity. Most studies in the 
review found women to be more dyspnoeic than men. Nonetheless, we could not obtain a 
credible pooled estimate due to low number of studies represented at the meta-analysis level. 
Also, individual studies highlighted possible gender disparities in medication prescription 
patterns. However, not enough studies have been done on each drug class and the two studies 
done on ICS use obtained a pooled effect that was not significant between genders. 
Our study findings are in agreement with five narrative reviews that have reported that: 
 1. There is COPD diagnosis bias in favor of men (10, 45-47). 
  2. Spirometry is mandatory to confirm a COPD diagnosis, but it is underused in women 
(10, 45). 
3. Women may experience a higher level of shortness of breath than men (10, 45-48). 
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4. Women with COPD experience a more impaired health-related quality of life than                                                 
men (10, 46-48). 
2.5.1 Study strengths   
We adhered to a strict priori inclusion and exclusion criteria for studies. Outcomes were 
chosen a priori, and studies that did not report the outcomes of interest were excluded. We 
abided strictly by standard procedures of conducting systematic reviews and meta-analysis, using 
the Cochrane approach, PRISMA and MOOSE checklists, and as such any differences will be 
attributed to chance or random error. Included studies were rigorously evaluated using the 
USPSTF quality rating criteria assessment of bias tool. Most studies chosen were cross-sectional 
in nature, which is an appropriate design to answer questions of this nature, to prove or disprove 
assumptions and create new theories for further studies.  
2.5.2 Study limitations 
All 4 studies that assessed “physician-diagnosed COPD” at the meta-analysis level were 
conducted in Spain and may only represent primary physician behaviour in Spain, but not in 
other countries or jurisdictions. Self-report of “physician-diagnosed COPD” may have 
introduced recall bias. Validated vignette questionnaires may not represent physician behaviour 
in real practice. Most of the studies used in the review were cross-sectional in design, and as with 
any cross-sectional association, it is not possible to determine a cause and effect relationship. 
Most studies presented effect measures as frequencies and percentages and this made meta-
analysis and hence credible conclusions on some outcomes, impossible. Studies of fair quality 
may have introduced bias that may compromise findings of this study. Lastly, publication bias 
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due to possible existence of unpublished studies with non-significant results may also 
overestimate findings of this review.  
2.6 Conclusion 
Our evidence suggests that primary care physicians may be less likely to suspect COPD 
when confronted by women with respiratory symptoms, than when confronted by men, and 
therefore less likely to refer them for spirometry. However, more studies need to be completed 
before concrete conclusions can be drawn. Women with diagnosis of COPD were found to have 
a lower health-related quality of life than men.  
2.6.1 Implications for further research and practice 
Studies on gender bias in the diagnosis of COPD should be updated and conducted across 
countries in a standardized fashion to see if the trend exists worldwide.  
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Summary of findings tables 
Table 2.1 Summary of findings for diagnostic outcomes (physician-diagnosed COPD/referral for spirometry) 
Article Study 
type/design 
Country/ patient 
population 
No. of men  No. of women  Outcomes assessed Results Adjusted variables 
Ancochea et al 
(2013) 
Cross-sectional Spain: A total of 
4274 subjects were 
randomly chosen by 
telephone in 11 
centres with mean 
age of 56.6. 
 
 
 
 
272 men were found to 
have COPD based on 
spirometry criteria 
114 
Women 
with 
COPD 
based on 
spirometry 
criteria 
Prevalence of COPD 
 Physician-diagnosed 
COPD, 
underdiagnoses, 
symptoms such as 
cough, sputum, 
dyspnea and 
wheezing.  
Men were more likely 
to be previously 
diagnosed with COPD 
 (RR=2.67, 1.14-6.26) 
Age, smoking, 
education level, mMRC 
dyspnea, COPD 
severity.  
Delgado et al 
(2016) 
Cross-sectional Spain: 457 family 
physicians were 
interviewed on 
primary care for 
COPD using 
validated vignette 
questionnaires.  
A case scenario of 135 men 
with COPD; 
Number of male physicians 
was 264 
 
A case scenario of 
173 women COPD; 
Number of female 
physicians was 193 
COPD as the most 
likely diagnosis, 
ordering of 
spirometry, referral to 
specialist, considering 
tobacco as major risk 
factor.   
Men were more likely 
to be diagnosed with 
COPD. (3.89, 2.097-
7.214) 
Men were more likely 
to be referred for 
spirometry (OR: 
2.323, 1.229-4.392). 
Adjusted for age of 
physician, gender of 
physician, postgraduate 
training.  
Miravitlles et 
al (2006) 
Cross-sectional Spain: 838 family 
physicians were 
surveyed on 
diagnostic attitudes 
towards COPD using 
validated vignette 
questionnaires 
A case scenario of 419  
male patients with COPD; 
Number of male family 
physicians were 419 
 
A case scenario of 
419 female patients 
with COPD; 
Number of female 
family physicians 
were 419 
COPD as the most 
likely diagnosis 
Men were more likely 
to be diagnosed with 
COPD(OR=1.55, 
1.15-2.1) 
Adjusted for age of 
physician, gender of 
physician, disease 
severity 
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Pena et al 
(2000) 
Cross-sectional Spain: A total of 
5827 participants 
were randomly 
contact via 
telephone. 
283men were found to have 
COPD based on spirometry 
criteria 
80 women with 
COPD based on 
spirometry criteria 
Prevalence of COPD 
prior physician 
diagnosis of COPD 
Men were more likely 
to be previously 
diagnosed with COPD 
(OR=1.77, 1.24-2.5) 
Age, educational level, 
smoking history, 
comorbidities.  
Watson et al 
(2004). 
Cross-sectional 
study 
United Kingdom: 
3265 subjects with 
Physician diagnosis 
of COPD, 
emphysema or 
chronic bronchitis 
were interviewed. 
All patients were 
aged 45 years and 
older. 
Out of the total subjects, 
1937 men were interviewed 
Total number of 
women with COPD 
were 1328. 
Management of 
COPD including ever 
had spirometry test, 
ever had smoking 
advice, 
hospitalization, ED 
visit, ICS use, ever 
had inhaler training. 
Women were less 
likely to have had 
spirometry (OR: 0.84, 
95% CI: 0.72-0.98). 
Adjusted for age, pack-
years of smoking, 
country and dyspnea 
severity. 
Shawn et al 
(2013) 
Retrospective 
cohort study 
U.S.A: 64985 
medicare beneficiary 
population who were 
newly diagnosed 
with COPD between 
1999 to 2008 
31547 men with copd 
diagnosis 
33438 women with 
copd diagnosis 
Spirometry performed 
within 365 days of the 
first claim with a 
COPD diagnosis. 
Women were less 
likely than men to 
have used spirometry 
(OR:0.96,95%  CI 
0.95-1.03) 
Age, sex, race,  
comorbidity  
Koefoed et al 
(2012) 
Retrospective 
cohort study 
Denmark: 40,969 
patients were 
identified through 
national registers 
from 2007 to 2010.  
19,083 men with 
obstructive lung disease 
21,886 women with 
obstructive lung 
disease. 
Spirometry use Women were less 
likely to have had 
spirometry(OR: 0.86; 
95% CI 0.82-0.9) 
Age, number of 
pulmonary medications 
received 
Roberts et al 
(2015). 
Cross-sectional 
study 
United Kingdom: A 
total number of 445 
participants with a 
provisional diagnosis 
of suspected COPD 
or definite COPD by 
a GP were referred to 
a community 
Respiratory unit. 
Overall, 81 men had a 
correct diagnosis of COPD 
participated 
Overall, 57 females 
had a correct 
diagnosis of COPD 
participated. 
Differences and role 
of spirometry in 
COPD patients. 
More men (87.5%) 
were significantly 
more likely to have 
their GP COPD 
diagnosis confirmed 
as compared to 73.9% 
of females (p=0.021).  
Age, sex 
 53 
Chapman et al 
(2001) 
Cross-sectional 
study 
Canada: A random 
sample of 192 
primary-care 
physicians (96 
Americans and 96 
Canadians) were 
surveyed. 
Out of the 192 primary care 
physicians surveyed, 154 
were men 
54 out of the total 
192 primary care 
physicians were 
women. 
Diagnosis of COPD 57% of the physicians 
offered COPD as the 
most likely diagnosis. 
More men (58%) 
were more likely to be 
diagnosed with COPD 
than women (42%) 
with p<0.05.  
 
Martinez et al 
(2012) 
Cross-sectional 
study 
USA: The study 
analysed data on 295 
females and 273 
male participants 
with COPD. 
273 men with COPD 295 females with 
COPD 
Symptoms, care 
delivery of COPD 
Women were more 
likely to report COPD 
diagnostic delay with 
adj OR 1.66 with 95% 
CI: 1.13-2.45, p=0.01.  
Other significant 
predictors were 
anxiety and history of 
exacerbations. 
Females were more 
likely to have 
difficulty in reaching 
their physicians. (OR 
2.54, 1.33-4.86). 
Adjusted for 
depression, use of 
oxygen, 
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Table 2.2 Summary of findings for cardinal COPD symptoms (Dyspnea, cough, and sputum production)  
Article Study 
type/design 
Country/ 
patient 
population 
No. of men No. of women Outcomes 
assessed 
Results Adjusted 
variables 
Katsura et al 
(2007) 
Cross-sectional Japan: 156 patients 
with copd at a 
teaching hospital 
117 men with COPD 
matched to women by age 
and FEV1 in a ratio of 3:1 
39  women with 
COPD 
dyspnea , health 
related quality of life, 
anxiety and 
depression 
Women had greater 
dyspnoea (=lower OCD 
dyspnea scores) than 
men(m75.1±1.6 vs 
w68.3±1.6)p<0.05 
 
Age, degree of airflow 
obstruction 
Watson et al 
(2004). 
Cross-sectional 
study 
USA: 3265 subjects 
with Physician 
diagnosis of COPD, 
emphysema or 
chronic bronchitis 
were interviewed. 
All patients were 
aged 45 years and 
older. 
Out of the total subjects, 
1937 men were 
interviewed 
Total number of 
women with COPD 
was 1328. 
Dyspnea, sputum, 
cough, 
hospitalization, 
emergency room 
visits , ever had 
spirometry test, ever 
had smoking advice, 
ICS use 
Women were 
significantly more likely 
to report dyspnea than 
men (OR: 1.30, 1.10-
1.54). 
Women were less likely 
to report sputum 
production(OR:0.84,0.72-
0.98) 
Women were as likely as 
men to report cough(OR: 
1.08, 0.92-1.27) 
 
Adjusted for age, 
pack-years of 
smoking, country and 
dyspnea severity. 
De Torres et al 
(2005) 
     Matched         
Case-series 
study  
Spain: 140 COPD 
patients attending a 
pulmonary clinic 
53 men with COPD were 
matched for FEV1. 
53 women with 
COPD matched 
with men with 
same FEV1 ±2% 
Dyspnea, quality of 
life, exacerbations in 
the last year 
Women reported higher 
degree of mMRC 
dyspnoea (28% vs 6%, 
p=0.05) 
 
FEV1 
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Lopez et al 
(2010) 
Cross-sectional 
study 
Uruguay: Total 
subjects eligible for 
the study were 6711. 
Out of this 5314 
completed 
questionnaire and 
spirometry test and 
759 were identified 
as COPD patients. 
Out of the 759 COPD 
patients 397 were males. 
And 362 were 
females. 
Health status 
perception, dyspnoea, 
physical activity. 
Female sex was found to 
be explaining dyspnoea 
(OR: 1.60, 1.40-1.84) and 
SF-12 physical score (OR 
-1.13, 95% CI -1.56- -
0.71).  
Age 
Marco et al 
(2006) 
Case-control Italy: A total number 
of 202 patients 
attending pulmonary 
clinic were 
compared to non-
patients on 
prevalence of 
symptoms were 
enrolled in the study. 
Male patients were 155. Female patients 
were 47. 
Anxiety and 
depression in COPD 
patients compared to 
controls. Secondary 
outcomes include 
symptoms, Quality of 
life (QoL) in men and 
women with COPD 
 Female patients had 
higher levels of dyspnea 
than men.  
 
Age 
Naberan et al 
(2012) 
Cross-sectional Spain: 4574 patients 
attending primary 
care and pulmonary 
clinics. Aged 40 
years and older 
3792 males with COPD 
diagnosis 
740 females with 
COPD diagnosis 
Quality of life, 
anxiety, depression, 
dyspnoea, sputum 
production, cough, 
exacerbations, 
emergency room 
visits 
Dyspnea was more 
frequent among females 
than males (60.1% vs 
55.1%, p=0.01)  while 
sputum production was 
more frequent among 
men. (73.3% vs 64.7%, 
p<0.001). Frequency of 
cough did not differ btw 
gender. (80. % vs 77.6%, 
p=0.75).  
Age, FEV1 
Ferrari et al 
2010 
Cross-sectional Brazil: 115 
consecutive COPD 
patients treated at 
the outpatient clinic 
of a single 
institution. 
60 men  were matched to 
the women in 2:1 ratio 
30 women  were 
matched to the 
women  
Dyspnoea, quality of 
life, BODE index, 
determinants of qol 
Women had greater 
dyspnea (=higher 
mmrc dyspnea 
scores) than men. 
Median,IQR 1(1-2) 
vs 2(1-3), p=0.05 
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Roche et al 
2014 
Cross-sectional  France: 688 COPD 
patients used for the 
analysis were 
recruited in an 
ongoing BPCO 
cohort study, from 
17 pulmonary units 
of  university 
hospitals located 
throughout France. 
275 men with COPD were  
matched to 107 women by 
age  and FEV1.(1:3) 
107 women with 
COPD were 
matched to 275 
men with COPD by 
age and FEV1. 
Dyspnea, quality of 
life, BOD index 
Women had greater 
dyspnea (=higher mmrc 
dyspnea scores) than 
men. 
Median, IQR 1(1-2) vs 
2(1-3), p=0.05 
Age, FEV1 
Raherison et al 
2014 
Cross- sectional France: 146 
physicians were 
made to recruit 446 
patients as they 
visited the clinics. 
183 men with COPD 247 women with 
COPD 
Quality of life, 
prevalence of cough, 
sputum production  
Frequency of cough 
(men, 75.6% vs women, 
78.5% p=NS) and sputum 
production (men 62% vs 
64.2% p=NS), did not 
differ significantly 
between genders. 
Age, FEV1 
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Table 2.3 Summary of findings for health-related quality of life 
Article Study 
type/design 
Country/ 
patient 
population 
No. of men No. of women Outcomes 
assessed 
Results Adjusted 
variables 
Katsura et al 
(2007) 
Cross-sectional Japan: 156 patients 
with copd at a 
teaching hospital 
117 men with COPD 
matched to women by age 
and FEV1 in a ratio of 3:1 
39  women with 
COPD 
dyspnea , health 
related quality of life, 
anxiety and 
depression 
More women had poorer 
quality of life than men 
(= higher SGRQ quality 
of life scores) (40% vs 
30%) p<0.001  
More women than men 
had lower scores 
(=poorer qol) for all 
domains of SF-36 quality 
of life questionnaire. 
 
Age, degree of airflow 
obstruction 
De Torres et al 
(2005) 
     Matched         
Case-series 
study  
Spain: 140 COPD 
patients attending a 
pulmonary clinic 
53 men with COPD were 
matched for FEV1. 
53 women with 
COPD matched 
with men with 
same FEV1 ±2% 
Dyspnea, quality of 
life, exacerbations in 
the last year 
Women had worse SGRG 
quality of life than 
men(44% vs 34%; 
p=0.08)  
 
FEV1 
Lopez et al 
(2010) 
Cross-sectional 
study 
Uruguay: Total 
subjects eligible for 
the study were 6711. 
Out of this 5314 
completed 
questionnaire and 
spirometry test and 
759 were identified 
as COPD patients. 
Out of the 759 COPD 
patients 397 were males. 
And 362 were 
females. 
Health status 
perception, dyspnoea, 
physical activity. 
Female sex was found to 
be explaining SF-12 
physical quality of life 
score (OR: 1.13, 95% CI 
-1.56- -0.71). More 
females reported their 
health status as fair-to-
poor. 
Age, FEV1 
Skumlien  
(2014) 
Cross-sectional 
study 
Norway: 110 COPD 
patients admitted for 
Total of 65 men with 
COPD 
45 women  with 
COPD  
Health related quality 
of life of COPD 
patients. 
No significant difference 
in SGRQ qol scores. 
Age, degree of airflow 
obstruction 
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pulmonary 
rehabilitation. 
(mean, SD: 56.5±16 vs 
58.7±14.1 ) 
Marco et al 
(2006) 
Case-control Italy: A total number 
of 202 patients 
attending pulmonary 
clinic were 
compared to non-
patients on 
prevalence of 
symptoms were 
enrolled in the study. 
Male patients were 155. Female patients 
were 47. 
Anxiety and 
depression in COPD 
patients compared to 
controls. Secondary 
outcome include 
symptoms, Quality of 
life (QoL) in men and 
women with COPD 
Higher levels of anxiety 
and depression was 
attributed to female 
patients and females 
recorded worse 
symptom-related QoL 
compared with men.   
FEV1 
Naberan et al 
(2012) 
Cross-sectional Spain: 4574 patients 
attending primary 
care and pulmonary 
clinics. Aged 40 
years and older 
3792 males with COPD 
diagnosis 
740 females with 
COPD diagnosis 
Quality of life, 
anxiety, depression, 
dyspnoea, sputum 
production, cough, 
exacerbations, 
emergency room 
visits 
Qol was assessed using  
3scales; 
Women showed poorer 
quality of life than men 
(=had lower EQ-5D 
index scores) mean,sd: 
(w0.6±0.3 vs m0.7±0.3; 
p<0.001).  
Women also had lower 
scores for EQ-5D VAS 
scale mean, sd: (57.3,17.3 
vs 59.7,16.4) p<0.001 
Women also had poorer 
qol using the AQ20 
quality of life 
questionnaire (higher 
scores= poorer qol. 
Mean, sd  (w10.4 ±4.6 vs 
m9.2±4.5, p<0.001) 
 
FEV1 
De Torres et al 
(2009) 
Retrospective 
cohort  
Spain: 1384 patients 
with COPD recruited 
from several clinics. 
272 men with COPD 
matched to 265 women by 
region and COPD severity. 
265 women with 
COPD matched to 
272 men by region 
and COPD severity. 
Mortality, quality of 
life.  
Women had worse 
quality of life than men(= 
higher SGRQ qol scores) 
age 
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mean ± SD: w48±19 vs 
m44±21) 
  
Low et al 
(2006) 
Cross-sectional Canada: 67 married 
community-dwelling 
older adults with 
COPD. 
43 men with COPD 24 women with 
COPD 
Quality of life Women had worse SIP 
Psychosocial HRQOL 
scores (13.3±13 vs 
10.5±12.2) p=0.02 
 
 
De Torres et al 
(2006) 
Matched case-
series 
Spain: 146 patients 
with COPD from a 
pulmonary clinic  
73 men with COPD 
matched with 73 women 
with similar degree of 
airflow obstruction  
 
73 women with 
COPD matched 
with 73 men with 
similar degree of 
airflow obstruction 
Quality of life  
Determinants of 
quality of life. 
Women had lower quality 
of life than men (=higher 
SGRQ scores ) (median, 
IQR-  w38 (30–47) vs 
m26 (15–52), p = 0.01 
FEV1 
Moro et al 
(2009) 
Cross-sectional Spain: Total of 9405 
patients recruited by 
general practitioners 
and pneumologists.  
1661 men matched with 
women by age and COPD 
severity 
1786 women with 
COPD  matched 
with men by age 
and COPD severity 
 
Quality of life 
Women had lower qol 
than men(=lower SF-12 
quality of life scores: 
Mean ±SD: w40.3±8.1 vs 
m43.5±7.6); p<0.0001 
`Age 
Celli et al 
(2011) 
Cross-sectional USA: total of 1,481 
women and 4,631 
men with COPD 
were enrolled in 
TORCH study 
4631 men with COPD 1481 women with 
COPD 
All-cause mortality 
Quality of life 
dyspnea 
Women had lower quality 
of life than men(= higher 
SGRQ qol scores) 
mean±SD:  m48.7 ±17.2 
vs w 51.3 ±16.6) 
FEV1 
Roche et al 
2014 
Cross-sectional France: 688 COPD 
patients used for the 
analysis were 
recruited in an 
ongoing BPCO 
cohort study, from 
17 pulmonary units 
of university 
hospitals located 
throughout France. 
275 men with COPD were  
matched to 107 women by 
age  and FEV1.(1:3) 
107 women with 
COPD were 
matched to 275 
men with COPD by 
age and FEV1. 
Dyspnea, quality of 
life, BOD index 
No significant difference 
between men and women 
in sgrq qol scores. 
Median, IQR: (m 43,30-
59 vs w 46 ,32-60) 
p=0.35 
Age, FEV1 
 60 
Raherison et al 
2014 
Cross- sectional France: 146 
physicians were 
made to recruit 446 
patients as they 
visited the clinics. 
183 men with COPD 247 women with 
COPD 
Quality of life, 
factors associated 
with health-related 
quality of life.  
Quality of life was more 
impaired in women than 
in men (=higher SGRQ 
scores for women) 
mean±SD:  50.6 vs 45.4 , 
p=0.019 
FEV1 
 
Table 2.4 Summary of findings for medication prescription patterns 
Article Study 
type/design 
Country/ 
patient 
population 
No. of men No. of women Outcomes 
assessed 
Results Adjusted 
variables 
 
Rinne et al 
(2017) 
Cross-sectional 
study 
(retrospective 
observational 
study) 
USA: 33,558 unique 
veterans with COPD 
admitted to 130 VA 
facilities were 
identified.+ 
32,409 men with COPD 
were identified. 
1149 women with 
COPD were 
identified. 
Primary outcome was 
prescriptions for 
baseline COPD 
medications. 
Secondary outcomes 
include severity of 
disease including 
LOS. 
Women were less likely 
than men to be 
prescribed with short-
acting beta agonists 
(SABA)  [OR, 95%CI 
0.83(0.72-0.95)] , 
SAMA(0.76(0.67-0.86), 
LABA(0.87(0.77-0.99), 
and  LAMA(0.74(0.63-
0.87).No difference in 
ICS(0.96(0.85-1.09) and 
oral steroids(1.01(0.88-
1.16) 
Women received fewer 
appropriate inhaler 
combinations with OR 
0.83 and 95% CI: (0.74-
0.93) and also women 
had more inappropriate 
drug combinations 
compared to men. 
Baseline characteristics 
such as age, race, 
health insurance, 
number of home ZIP 
codes in the year prior 
to hospitalization, and 
discharge against 
medical device were 
controlled for. 
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Similar rates of inhaled 
steroids were prescribed 
for both men and 
women. Hospital 
outcomes were similar. 
Watson et al 
(2004). 
Cross-sectional 
study 
USA: 3265 subjects 
with Physician 
diagnosis of COPD, 
emphysema or 
chronic bronchitis 
were interviewed. 
All patients were 
aged 45 years and 
older. 
Out of the total subjects, 
1937 men were interviewed 
Total number of 
women with COPD 
was 1328. 
ICS use, 
Dyspnea, sputum, 
cough, 
hospitalization, 
emergency room 
visits , ever had 
spirometry test, ever 
had smoking advice 
No difference between 
gender in ICS use  
OR,95% CI : 1.01 
(0.84,1.21) 
Adjusted for age, pack-
years of smoking, 
country and dyspnea 
severity. 
Cydulka et al 
(2005) 
Prospective 
cohort study 
USA & Canada: 579 
patients with 
exacerbation of 
asthma and or COPD 
were enrolled. Total 
of 397 patients with 
physician-diagnosed 
COPD were used. 
One cohort 
comprises 224 
patients with COPD. 
173 patients were 
having mixed COPD 
and asthma. Had 
average age of 68 
years. 
191 men with diagnosis of 
COPD 
206 Women with 
diagnosis of COPD 
ED visits with 
exacerbation of 
COPD 
Women used   inhaled 
corticosteroids with 
same frequency as men  
(ICS)  (%) 47% vs 51% 
p=0.44 
More men were on 
anticholinergics (69% 
vs 59%) p=0.04 
 
age, pack-years 
Sherman et al 
(2005) 
Cross-sectional USA: 1941 smokers 
with COPD with at 
least 3 with at least 3 
primary care visits to 
the hospital 
1812 males smokers with 
COPD 
129 female smokers 
with COPD 
Prescription for 
nicotine patches 
Advice for smoking 
cessation 
Females were less likely 
to receive a prescription 
for nicotine patches or 
gums (OR 0.5, 95% CI 
0.3–0.9).  
Age 
Carrasco-
Garrido et al 
(2009) 
observational 
and descriptive 
Spain: COPD 
patients were 
recruited from health 
8097 men with COPD 2613 women with 
COPD 
COPD treatment, 
quality of life. 
Men received a larger 
number of drugs for 
COPD than women.  
packyears 
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epidemiological 
study 
centres and medical 
records and through 
physicians. 
significantly greater 
among males was the 
percentage use of long-
acting b2-adrenergic 
agonists (9.8% vs7.9% 
in females, p < 0.05),  
anticholinergic drugs 
(85.6%vs 82.4%, p < 
0.05),  
theophyllines (13.2% vs 
7.6%, p <0.05) and 
mucolytic agents (9.3% 
vs 7.7%, p < 0.05). 
no gender differences 
were recorded in the 
frequency of 
prescription of inhaled 
corticosteroids –  
(22.1% in males vs 
22.2% in females)  
and oral corticosteroids 
(4.4% vs 
5.3%). 
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Assessment of bias Tables 
Table 2.5 Assessment of bias of articles using USPSTF Quality criteria for Cohort studies 
Article Assembly 
of 
comparable 
groups 
Maintenance 
of 
comparable 
groups 
No 
important 
differential 
loss to 
follow-up 
or overall 
high loss 
to follow-
up 
Measurements: 
equal reliable, 
valid (includes 
masking of 
outcome 
assessment) 
Clear 
definition 
of 
intervention 
All-
important 
outcomes 
considered 
Analysis: 
Adjustment 
for potential 
confounders 
Overall 
assessed 
quality 
Shawn et 
al(2013)- 
retrospective 
cohort 
good good fair good good good good Good 
Koefoed et 
al (2012)- 
retrospective 
cohort 
good good fair good good good good Good 
De Torres 
(2009)- 
retrospective 
cohort  
good good fair poor good good good Fair 
Cydulka et 
al (2005) 
good unclear poor fair fair good good Fair 
Roche et al 
(2014) 
retrospective 
cohort 
good good good fair good fair good Good 
 
Table 2.6 Assessment of bias of articles using USPSTF Quality criteria for Case-control and 
Cross-sectional studies  
Article Accurate 
ascertainment 
of cases 
Non-biased 
selection of 
cases/controls 
with 
exclusion and 
inclusion 
applied to 
both 
Response 
Rate 
Diagnostic 
testing 
procedures 
applied equally 
to each group 
Measurement 
of exposure 
accurate and 
applied 
equally to 
each group 
Appropriate 
attention to 
potential 
confounding 
variable 
Overall 
assessed 
quality 
Ancochea et al good good good good fair good Good 
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(2013) – cross-
sectional  
Delgado et 
al(2016)- cross-
sectional 
good fair good good fair good Good 
Miravitlles et 
al(2006) - cross-
sectional 
fair fair good good fair good Fair 
Pena et 
al(2000)- cross-
sectional 
good good good unclear fair good Good 
Watson et al 
(2004)- cross-
sectional 
fair unclear good fair fair good Fair 
Roberts et al 
(2015)- cross-
sectional 
good unclear fair good fair good Fair 
Chapman et al 
(2001)- cross-
sectional 
unclear unclear fair good fair poor Poor 
Martinez et al 
(2012)- cross-
sectional 
fair unclear good fair good good Fair 
Katsura et al 
(2007) - cross-
sectional 
good fair good  fair fair good  Fair 
De Torres et al 
(2005)- case 
series 
good good good good fair fair Good 
Lopez et al 
(2010) - cross-
sectional 
fair unclear good fair good good Good 
Skumlien 
(2014) - cross-
sectional 
good fair fair fair fair good Fair 
Marco et al 
(2006) – case-
control 
fair fair fair unclear fair good Fair 
Naberan et al 
(2012) - cross-
sectional 
good good good unclear fair good Good 
Low & Gutman 
(2006)- cross-
sectional 
good good good good fair good Good 
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De Torres et al 
(2006)- case-
series 
good good good unclear fair good Fair 
Moro et al 
(2009)- cross-
sectional 
good good good good fair unclear Good 
Celli et al 
(2011)- cross-
sectional 
good fair good unclear fair unclear Fair 
Rinne et al 
(2017)-Cross-
sectional study 
good good fair good good good Good 
Sherman et al 
(2005) – cross-
sectional 
good good good unclear fair unclear Fair 
Rahison et al 
2014 - cross-
sectional 
good good good fair fair fair Fair 
Ferrari et al 
2010 - cross-
sectional 
good  good fair good fair good Good 
Carrasco-
Garrido et al 
(2009)- cross-
sectional 
good good  good fair fair unclear Fair 
 
 
Table 2.7 Test for funnel plot asymmetry 
 
Egger’s regression 
Intercept -1.08486 
Standard error 4.12907 
95% lower limit (2-tailed) -10.84857 
95% upper limit (2-tailed) 8.67884 
t-value 0.26274 
df 7.00000 
P-value (1-tailed) 0.40016 
P-value (2-tailed) 0.80032 
  
Begg and Mazumdar rank correlation 
Kendall’s S statistics (P-Q) -10.00000 
Kendall’s tau without continuity 
correction 
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Tau -0.27778 
z-value for tau 1.04257 
P-value (1 tailed) 0.14857 
P-value (2-tailed) 0.29715 
Kendall’s tau with continuity correction  
Tau -0.25000 
z-value for tau 0.93831 
P-value (1 tailed) 0.17404 
P-value (2-tailed) 0.34808 
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CHAPTER THREE 
 
Research Study #2: Examining Gender Differences in the Diagnosis 
of Obstructive Airway Diseases in Patients with Shortness of Breath 
with Prescription for Inhaler Medications  
 
 
 
 
 
A version of this chapter will be submitted to the Journal of COPD 
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3.1 Abstract 
Background: There is evidence from across Europe that gender differences exist in the 
diagnosis of COPD. Available data suggests that women with COPD may be less likely to 
receive a doctor’s diagnosis of the disease. We sought to investigate any potential gender 
disparities in the diagnosis of COPD and asthma from family practice physicians, using data 
collected in the Epidemiology of Shortness of Breath (EpiSOB) study conducted in Alberta and 
Saskatchewan, Canada. As a secondary objective, we explored differences in medication 
prescription patterns, symptoms and health-related quality of life of men and women with COPD 
or asthma. 
Methods: The population was 328 patients with shortness of breath. Standard diagnosis of 
COPD, asthma and other respiratory conditions was made by expert pulmonologists at the time 
of the study using guidelines-approved methods (ATS/ERS criteria) of diagnosis. Data on 
physician-diagnosed COPD or asthma, referral for spirometry and other diagnostic outcomes 
were obtained from participants through structured questionnaires. Medical records were 
assessed for medication prescription patterns of physicians.  
Analysis: Diagnostic outcomes, symptoms and medication prescription patterns of men and 
women were compared using descriptive statistics. Multivariate logistic regression was used to 
assess the effect of sex on physician-diagnosed COPD or asthma, misdiagnosis, referral to see a 
specialist, referral for spirometry, referral for chest x-ray and referral for methacholine tests 
while controlling for additional patient factors. 
Results: Out of the 328 patients with shortness of breath, 97 patients were identified with COPD 
and 149 with asthma by expert pulmonologists at the time of the study, mainly using 
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spirometry. After accounting for confounders, no significant difference was observed between 
genders for all diagnostic outcomes in patients with spirometrically-defined COPD.  However, in 
patients with spirometrically-defined asthma, women were significantly less likely than men to 
have a physician-diagnosed asthma (OR=0.535, 95%CI: 0.295-0.969, p=0.039) and less likely to 
be referred for spirometry (OR=0.446, 95%CI: 0.200-0.994, p=0.048), but more likely than men 
to be referred for chest x-rays (OR=2.062, 95%CI: 1.030-4.128, p=0.041).  
Conclusion: This study did not provide support for the existence of gender disparities in the 
diagnosis of COPD. However, we found some evidence of gender inequalities in primary care 
for asthma in this study. More studies with larger sample size are required to draw concrete 
conclusions. 
Keywords: gender differences, family physicians, primary care, gender disparities, gender bias, 
COPD, asthma.  
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3.2 Introduction 
The medical profession strives for equal treatment for all patients. Nonetheless, 
disparities in health care are prevalent (1). “Cultural stereotypes may not be consciously 
endorsed, but their mere existence influences how information about an individual is processed 
and leads to unintended biases in decision-making, so called ‘implicit bias’”- Elizabeth N. 
Chapman (1). Physician behavior and practices may be unconsciously shaped by experience, 
prejudice or intuition, leading to differences in medical treatments and to healthcare disparities 
(1). Disparities in health services utilization may impact health outcomes of patients. 
There is increasing evidence to support gender bias in the diagnosis of COPD. Being 
stereotyped as a disease of men for many years, the notion that a woman with respiratory 
symptoms is less likely to have COPD has lingered over time. Particularly, women have more 
often reported a delay in COPD diagnosis and have been less likely to receive a correct diagnosis 
for COPD as compared to men (2-7). A systematic review conducted by our research group 
found that the odds of having a previous doctor diagnosis in people who meet spirometry criteria 
for COPD was 2.09 (95%CI: 1.44–3.05) for men versus women, after controlling for potential 
confounders (8). This finding may however only represent Spanish physician behavior, as all the 
four studies included in the meta-analysis were from Spain. Physician diagnosis and treatment 
patterns for men and women in Canada are yet to be ascertained.  
Women have been reported to be less likely to be prescribed some classes of COPD 
medications and have also been reported to have lower health-related quality of life and more 
dyspnea than men (7, 9-12). Though little is known about a bias in asthma diagnosis, this 
condition has often been the next most likely differential diagnosis for COPD (13-15). It is 
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possible that some women diagnosed by family physicians as having asthma may meet the 
spirometry criteria for COPD or other obstructive airway diseases instead (5, 16) . The analysis 
presented in this study examined physician diagnostic behavior for patients with shortness of 
breath who meet spirometry criteria for COPD or asthma. As a secondary objective, we explored 
medication prescription patterns, symptoms and health-related quality of life of men and women 
who meet guideline criteria for COPD or asthma. 
3.3 Methods 
3.3.1 Study design and participants 
This study is a cross-sectional secondary analysis of primary data from the Epidemiology 
of Shortness of Breath (EpiSOB) study conducted between 2009 and 2013.The methods and 
materials for the EpiSOB research program have been described in full details elsewhere (17). In 
brief, the baseline sample of the EpiSOB program was a cross-sectional survey of community 
patients who had been prescribed an inhaler medication for relief of shortness of breath 
symptoms, by their family physicians. The primary aim of the study was to determine the disease 
status of community patients with shortness of breath, using guidelines-approved methods of 
diagnosis, and then compare the research finding to the diagnosis given to them by their primary-
care physicians.  
Community pharmacists recruited all patients with inhaler prescriptions. Eligible 
respondents were enrolled after obtaining informed consent. Subjects were eligible if they were 
18 years and older. Another inclusion criteria was if subjects had an active or recent prescription 
(within the past six months) for any one of the following class of medications: short-acting beta-
2-agonist (SABA), short-acting anticholinergic (SAAC), long-acting beta-2-agonist (LABA), 
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long-acting anticholinergic (LAAC), as well as combination products and inhaled 
corticosteroids, prescribed by their family physicians for relief of their shortness of breath 
symptoms.  Patients were excluded from the study if they were unable to communicate in 
English, unable or refused to take a physical exam and pulmonary function tests (PFTs), 
pregnant, or did not provide a signed informed consent form.  
Three hundred and eighty-four (384) patients from Edmonton and 91 from Saskatoon 
gave consent but a total of 328 patients were available for spirometry testing and analysis. The 
EpiSOB study was funded by ASTHMA-C project council, The Alternate Reimbursement Plan 
Innovation fund, Capital Health of the Alberta Health Services and Alberta Health and Wellness, 
and was authorized by the ethics committees at the University of Alberta (# 7530) and the 
University of Saskatchewan (Bio-REB # 09-132).  
3.3.2 Study Measures 
Pre-post-bronchodilator spirometry and methacholine challenge testing was performed by 
trained and certified technicians at the time of the study according to procedures recommended 
by the standard manual of the American Thoracic Society (ATS) (18). COPD was defined as 
post-bronchodilator FEV1 <80% predicted, together with an FEV1/FVC <0.70. Asthma was 
defined as an increase in FEV1 by 12% or 200 mL after bronchodilation or a positive response to 
a methacholine test.  In cases where PFT data did not provide the clear indication of asthma or 
COPD diagnosis, a two-third consensus was sought from three expert pulmonologists.   
3.3.3 Questionnaire data 
Patients were asked to complete a questionnaire on socio-demographic factors, smoking 
history, comorbidities, respiratory symptoms, previous emergency room visits and 
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hospitalizations, family physician’s diagnosis and previous test procedures performed for 
diagnostic evaluation for shortness of breath. Additionally, patients were asked to complete an 
asthma control questionnaire (ACQ) and a COPD assessment test (CAT) survey for 
measurement of their health-related quality of life. Pharmacists also presented a list of 
medications each patient was using within the past six month. 
3.3.4 Definition of outcome variables 
Physician-diagnosed COPD was defined as patient self-reported diagnosis of COPD from 
a family physician. Physician-diagnosed asthma was defined as patient self-reported diagnosis of 
asthma from a family physician. Misdiagnosis of COPD was considered when participants had 
post bronchodilator FEV1 /FVC <0.7, but were given a diagnosis for asthma by a family 
physician. Misdiagnosis of asthma was considered when participants showed airway reversibility 
(increase in FEV1 by 12% or 200 mL with respect to baseline) but was given a diagnosis for 
COPD by a family physician. A prior test was defined as performed when the question, “have 
you ever had any of the following tests for your SOB symptoms- spirometry, chest x-ray, and 
methacholine?” was answered affirmatively.  This information was also confirmed from the 
patient records. 
Physician-diagnosed COPD or asthma was based on questionnaire response “Has your 
family physician ever given you a diagnosis for your shortness of breath symptoms? If yes, what 
diagnosis?”.  The reported diagnosis of COPD or asthma was considered correct if it matched 
spirometry results at the time of the study visit. Referral to see a specialist was based on 
questionnaire response “Have you ever seen a specialist for your shortness of breath symptoms? 
If yes, were you referred by your family doctor?” 
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3.3.5 Sample Size Considerations 
This is a secondary analysis of primary data of a cross-sectional survey, the EpiSOB 
study. Approximately, 384 participants were obtained from Edmonton and 91 from Saskatoon, 
however, 328 samples were used for analysis. Power calculations using a type I error rate of 5%, 
incidence rates derived from the literature and assumed 2-sided test conducted using Stata and 
command prompt stpower cox are summarized in Table 3.1 for primary outcomes.  
From the power calculations conducted, this study has at least a power of 0.1701 to detect 
an effect size of 1.5 and a power of 1.000 to detect an effect size of 5.0. A similar study 
conducted, the EPI-SCAN study, had 386 participants with COPD (2). Also, in another study by 
Leynaert et al., 769 participants with asthma-like symptoms and bronchial hyper-responsiveness 
were used (19). Lastly, in a study by Pena et al., 363 patients with COPD were used (20). 
3.3.6 Data analysis 
All statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS) version 22. Continuous variables were described using specific measures of central 
tendencies such as mean and standard deviation. Categorical variables were summarized using 
frequency tables and proportions. Significance tests between men and women were conducted 
using t-tests for continuous variables and chi-square tests for categorical variables. Univariate 
analysis was carried out for all potential confounders. Any variable having a significant 
univariate test at 0.2 levels was selected as a candidate for the multivariate analysis. Logistic 
regression, using the backward variable selection procedure, was used to assess the influence of 
sex (with male as the reference) on physician-diagnosed COPD or  asthma, misdiagnosis, referral 
to a specialist, referral for spirometry, referral for chest x-ray and referral for methacholine tests, 
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while controlling for potential confounders. Statistical significance level was set at p < 0.05 and 
individual estimators were overlapped with 95% confidence intervals. 
3.3.7 Ethics consideration 
The gender study presented in this chapter has received ethical approval from the 
Provincial Human Research Ethics Board (HREB) at the Memorial University of Newfoundland 
(#2018.138) 
3.4 Results 
3.4.1 Characteristics of participants   
The sociodemographic and baseline characteristics of the 328 participants with shortness 
of breath in the EPI-SOB study corresponded to 140 (42.7%) men and 188 (57.3%) women 
(Table 3.2). The cohort had an average age of 49 years. The race of the cohort was distributed as 
follows: 86% were Caucasians and 14% Black, Aboriginal, Hispanic, or Oriental. A greater 
percentage of women than men were Caucasians (90.4% vs. 80.7%, p=0.011). There were fewer 
smokers among the women (p=0.05), and women had fewer pack years, better oxygen saturation 
(p=0.002) and better spirometry values for % predicted FEV1 (p=0.001), FVC (p= 0.022), 
FEV1/FVC (p=0.002) and PEF (p=0.02) at baseline. The comorbidities allergies, osteoporosis, 
depression, anxiety and anemia were reported more often in women than in men, while more 
men than women reported coronary artery disease (CAD). All other sociodemographic and 
clinical variables did not differ significantly between men and women. 
Among the 97 participants with spirometrically-defined COPD, 51 (52.6%) were men 
and 46 (47.4%) were women (Table 3.3). The average age of all COPD participants was 62 
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years. The comorbidities osteoporosis and depression were reported more often in women than in 
men. Heart rate and respiratory rate were significantly higher for women than men. All other 
sociodemographic and clinical variables did not differ significantly between men and women. 
Among the 149 participants with spirometrically-defined asthma, 62 (41.6%) were men 
and 87 (58.4%) were women (Table 3.4). The average age of all asthma participants was 43 
years.  A greater percentage of women than men were Caucasians (77.4% vs. 94.3%, p=0.002). 
Women had fewer pack years of smoking and better spirometry values for percent-predicted 
FEV1 (p=0.00), FVC (p= 0.042), FEV1/FVC (p=0.001) and PEF (p=0.00). Hypertension was 
reported more often in men than in women while depression and anemia were most often 
reported by women as their comorbidity.  All other comorbidities were reported with the same 
frequency amongst men and women. 
3.4.2 Symptoms 
For patients with COPD, women reported more severe dyspnea than men (MRC 3-4: 
37% vs 23.5%).  However, the difference failed to reach statistical significance (p= 0.149) 
(Table 3.5 and Figure 3.3). Again, with respect to other respiratory symptoms, there were no 
significant differences by sex in frequency of nocturnal cough, sputum production, chest 
tightness or wheeze. Levels of fatigue and hospitalization for respiratory conditions were higher 
in women than in men, but again failed to reach statistical significance. 
For participants with asthma, the less severe end of the dyspnea spectrum recorded more 
men than women, while the more severe end recorded more women than men. Again, the 
difference was not statistically significant. With respect to other respiratory symptoms, there 
were no significant differences by sex in nocturnal cough, sputum production, chest tightness or 
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wheeze. However, fatigue was significantly more common in women than in men (p=0.039) and 
more women than men reported having had a recent hospitalization or emergency room visit 
(p=0.026) (Table 3.5 and Figure 3.4). 
3.4.3 Health-related quality of life 
Women with COPD had higher scores for all domains of the COPD Assessment Test 
(CAT), indicating a greater impact of disease on health-related quality of life for women than for 
men (Table 3.6). However, statistically significant levels were reached for only two of the 
domains. Specifically, women reported more breathlessness when walking up a hill (p=0.04) and 
fewer women were comfortable leaving home (p=0.05).  The overall CAT score failed to reach 
statistical significance (p=0.09). 
There was no trend in Asthma Controlled Questionnaire (ACQ) scores for men and 
women with asthma. Impairment was generally low for both genders in all the domains. 
However, men had significantly higher scores for the domain “How many times did you 
wheeze?” indicating more impairment for that domain. Total ACQ score was not different 
between men and women (Table 3.7).    
3.4.4 Pharmacological Treatment 
Table 3.8 compares men and women in terms of medication prescription patterns. For 
patients with COPD, there were no significant differences between men and women in the use of 
beta agonists, corticosteroids, anticholinergics, methylxantines or leukotriene receptor 
antagonists (LTRA). 
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For patients with asthma, significantly more men than women were on SABA (p=0.038).  
Frequency of use of all other drug classes did not differ significantly between men and women 
with asthma. 
3.5.5 Comparing family physician’s diagnosis of patients with spirometrically-defined 
COPD 
Table 3.9 and Figure 3.1 summarize primary-care physicians’ diagnostic patterns for men 
and women who met spirometry criteria for COPD. Out of 97 patients with COPD by spirometry 
criteria, only 24 (24.7%) had had a diagnosis of COPD from their family-care physician. This 
number was unevenly distributed by gender, being 21.6% for men and 28.3% for women. Forty-
five (46.4%) patients with spirometrically-defined COPD were misdiagnosed with asthma by 
family physicians, and this represented 47.8% women and 45.2% men. Also, 23% women and 
22% men were referred by their family physician to see a specialist. Only 49 (50.5%) of all 
COPD patients reported a previous spirometry performed, representing 54.9% men and 45.7% 
women. Again, 73.9 % women and 64.7% men had had chest x-ray, and only 2 out of 97 
spirometrically-defined COPD patients reported a methacholine test, 2.2% women and 2.0% 
men.  
On univariate analysis, sex (male as reference) was not significantly associated with 
physician-diagnosed COPD (correct diagnosis), physician-diagnosed asthma (misdiagnosis), 
referral to a specialist, referral for spirometry or referral for chest x-ray. Other variables that 
were associated with diagnostic outcomes at a level of p-value < 0.2 were age, weight, marital 
status, educational status, smoking history, FEV1/FVC, cough, total CAT score, fatigue, allergy 
and comorbidities as shown in Table 3.10. 
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After adjusting for potential confounding factors, and forcing sex into the model in 
multivariate analysis, the  non-significant results persisted. Sex was not significantly associated 
with any of the primary outcome measures (see Table 3.11).  Multivariate analysis was not 
possible for “referral for methacholine” due to the small number of people (<3) who had that test 
performed.  
3.5.6 Comparing family physician’s diagnosis of patients with spirometrically-defined 
asthma 
Table 3.9 and Figure 3.2 summarize primary-care physicians’ diagnostic patterns for men 
and women who met spirometry criteria for asthma. Out of 146 patients with asthma by 
spirometry criteria, 102 (68.5%) reported a family physician’s diagnosis of asthma, and this 
comprised 74.2% men and 64.4% women. Also, out of 146 patients with spirometrically-defined 
asthma, 9 (6%) were misdiagnosed with COPD by their family physician, and this group 
comprised 9.7% men and 3.4% women. Out of those referred to see a specialist, 27.6% were 
women and 25.8% were men. Also, 43.5% men and 28.7% women were referred for spirometry. 
Referrals for chest x-ray were more in women (47.1%) than in men (27.4%). Also, 1.6% men 
and 0% women reported a methacholine test.  
On univariate analysis, sex (male as reference) was significantly associated with referral 
for chest x-ray (OR=2.359, 95%CI: 1.173-4.746, p=0.016). However sex was not significantly 
associated with physician-diagnosed asthma (correct diagnosis), physician-diagnosed COPD 
(misdiagnosis), referral to a specialist, or referral for spirometry at 0.05 levels. Other variables 
that were associated with diagnostic outcomes at a level of p-value < 0.2 were age, educational 
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status, pack years, FEV1% predicted, total ACQ score, respiratory rate, dyspnea, cough, allergy 
and comorbidities (Table 3.12). 
After adjusted models for patients with spirometrically-defined asthma, sex was found to 
be significantly associated with physician-diagnosed asthma, referral for spirometry and referral 
for chest x-ray. Women were found to be less likely than men to have had a physician diagnosis 
of asthma (OR=0.535, 95%CI: 0.295-0.969, p=0.039), less likely to be referred for spirometry 
(OR=0.446, 95%CI: 0.200-0.994, p=0.048), but more likely than men to be referred for chest x-
rays (OR=2.062, 95%CI: 1.030-4.128, p=0.041). All other diagnostic outcomes failed to reach 
statistical significance as depicted in Table 3.13.  Again, multivariate analysis was not possible 
for “referral for methacholine” due to the small number of people (<3) who had that test 
performed.  
3.5 Discussion 
In our study, there were no significant differences between men and women in terms of 
physician-diagnosed COPD, referral to a specialist or referral for spirometry and other diagnostic 
tests in patients with spirometrically-defined COPD. In addition, there were no significant 
differences between gender in overall dyspnea and health-related quality of life scores. No 
difference was seen for cough, sputum production or medication prescription patterns. 
Comparing these results to those of previous studies however, reveals contradictory findings. For 
instance, in the EPI-SCAN study, male sex was found to be significantly associated with a 
previous diagnosis of COPD (2). Also in the Confronting COPD study, women with respiratory 
symptoms were found as less likely to have had a referral for spirometry, with three other studies 
corroborating that finding (3, 7, 21, 22). On the other hand, although a number of previous 
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studies have associated female sex with more dyspnea and poorer health-related quality of life, a 
study by Skumlien et al. found no significant difference between genders (23).  
Results of this study however corroborate previous findings that underdiagnoses of 
COPD is generally high in both men and women, and in line with reports by other studies, less 
than 30% of people who meet spirometry criteria for COPD actually had a previous physician’s 
diagnosis for their condition (2).  Also, the number of people with COPD who were 
misdiagnosed with asthma was as high as 46.4% for both men and women alike. Guidelines for 
COPD recommend spirometry as the ‘gold standard’ in the evaluation of patients with 
respiratory symptoms suggestive of COPD (24). Spirometry can be used to confirm obstruction 
in airways and to differentiate COPD from asthma (24, 25). In our cohort, referrals for 
spirometry were as low as 50.5% for both men and women, and this corroborates results from 
previous studies (26, 27).  
Men and women with spirometrically-defined asthma in our cohort had similar age and 
BMI, but men had smoked more than women. Women with asthma reported higher levels of 
fatigue and more emergency room visits than men. After controlling for confounders, women 
were less likely than men to be given a correct diagnosis for asthma, less likely to be referred for 
spirometry, but more likely to be referred for chest x-ray.  
Evidence on diagnostic bias in asthma is limited. It has been suggested that COPD is 
more likely to be misdiagnosed as asthma in women than in men (5), but we do not know if 
women are also more likely to have a physician’s diagnosis of asthma, amongst men and women 
who both meet guidelines criteria for asthma. Interestingly, we found that women in our cohort 
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of asthma patients were less likely to receive a physician’s diagnosis of the disease after 
controlling for confounders.  
Although we were expecting women to be more likely to be diagnosed with asthma since 
asthma has been subtly tagged as a “woman’s disease” especially after the age of 35 years (5, 
19), it is however possible that apart from known physician stereotypes, there is a general 
underestimation or misunderstanding of women’s risk for health problems or complications (28). 
Another factor may be due to differences in the way men and women report their symptoms to 
the physician, as this could influence diagnostic decisions. Women tend to describe what they 
experience using a more personal, narrative approach as compared to men, who typically 
describe symptoms in a more straightforward, factual manner with fewer comments (7, 28). 
Women’s narrative presentation style may contribute to physicians making more diagnostic 
errors in their evaluations of conditions, and especially when the use of objective measures of 
diagnosis are minimal (28). 
Authors of GINA guidelines recommend that the diagnosis of asthma be based on the 
history of characteristic symptom patterns and evidence of variable airflow limitation, confirmed 
by spirometry (25). As reported by previous studies however, spirometry use in primary care 
diagnosis remains low, as less than 40% of patients had had a previous spirometry in our cohort. 
Why women should receive even less referrals for spirometry is difficult to explain. 
On the other hand, more women than men were referred for chest x-ray. Given that chest 
x-ray is not a lung function test, and could be indicated for varied reasons (for example, as a tool 
in the examination of patients with an exacerbation of asthma or as an initial imaging evaluation 
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in individuals with symptoms of asthma (29) ), it is unclear why more women than men were 
referred for chest x-rays. 
It has been reported that women suffer from asthma symptoms and exacerbations more 
frequently and more severely than men (30, 31). We however found no significant differences 
between genders for dyspnea, cough or health-related quality of life. Women in our cohort however 
reported higher levels of fatigue and more frequent hospitalization than men. They also reported 
higher frequencies of comorbidities like anxiety, depression and osteoporosis, than men but lower 
frequency of hypertension. It is unclear to what extent these data are influenced by physician bias 
or differences in the care received. Lastly medication prescription patterns were similar for both 
genders, except for short acting beta agonists that were prescribed significantly more often in 
women than men. 
There are several limitations to this study. Firstly, our patients were recruited from people 
with shortness of breath attending community pharmacies for medications and may therefore not 
represent the entire COPD or asthma population at large. Our cohort of patients appears to have 
mild disease (i.e. average FEV1% predicted of >70%), and this may have impacted the findings of 
the study. Again, there were marked differences in baseline characteristics. Although variables 
that were strongly associated with the primary outcomes were adjusted for in the multivariate 
analysis, there is the possibility of residual confounding influencing findings of the study. Also, a 
very small number of respondents for some sub analysis may have impacted the results, while the 
many statistical tests increase the probability of a type I error. Even though physician-diagnosed 
asthma, referral for spirometry and referral for chest x-ray showed significant differences between 
men and women, the wide confidence intervals associated with the odds ratio may be due to the 
 84 
small number of patients with spirometrically-defined asthma in the study sample. Moreover, 
patients recruited in this study were all 40 and older, and it is not clear whether this finding can be 
applied to all age groups. Another limitation of this study is that it relies heavily on self-response. 
Even though some outcomes were validated by a crosscheck with patients’ records, we cannot rule 
out the possibility of recall bias.  
3.6 Conclusion 
There is some evidence of gender inequalities in primary care for asthma in this study. 
More studies with larger sample size are still required to draw concrete conclusions. 
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Table 3.1 Power calculations for physician diagnoses of COPD and asthma, the primary 
outcome of the study 
Outcome Exposure Incidence   
in the 
population 
(reference) 
Effect Size 
of 1.5 
Effect Size 
of 2.0 
Effect Size 
of 2.5 
Effect Size 
of 3.5 
Effect Size 
of 5.0 
Physician 
diagnosed 
COPD 
Women 7.51 (2) 0.1701 0.4052 0.6232 0.8747 0.9790 
Physician 
diagnosed 
COPD 
Men 19.70 (2) 0.3706 0.7956 0.9575 0.9989 1.0000 
Physician 
diagnosed 
asthma 
Women 17.03 (19) 0.3282 0.7357 0.9284 0.9968 1.0000 
Physician 
diagnosed 
asthma 
Men 13.70 (19) 0.2739 0.6418 0.8668 0.9874 1.0000 
All the above calculations were based on assumed two-sided alpha of 0.05 and expected event 
rates from previous studies; and a data consisting of 328 patients with shortness of breath, of 
which 97 were COPD patients and 149 were asthma patients. 
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Table 3.2 Sociodemographic and clinical characteristics of 328 participants of the EPI-SOB 
study, by sex.  
 Men 
#(%) 
Women 
#(%) 
p-value 
 
No. of Participants 140(42.7 ) 188(57.3)  
Age in years (mean ± SD): 50.8±18.3 48.2±17.9 0.209 
AGE1   0.406 
Ages< 50 65(46.4) 96(51.1) 
 
Ages >50 75(53.6)  92(48.9)  
Marital status:     0.282 
Single/Never Married 
Separated/Divorced/Widowed 
Married/Common-Law 
 38(27.1) 
17 (12.1) 
 85(60.7) 
 48(25.5) 
 35(18.6) 
105 (55.9) 
 
Educational status:   0.202 
Post-Secondary Education  63(45)  98(52.1) 
 
Other 77(55) 90(47.9)  
Race:   0.011 
Caucasian 
Other  
113 (80.7) 
 27(19.3) 
 170(90.4) 
 18(9.6) 
 
Smoking history:   0.05 
Current 
Past  
Never smoked  
 26(18.6) 
 60(42.9) 
54(38.6) 
 39(20.7) 
 57(30.3) 
92(48.9) 
 
Second hand exposure to 
cigarette smoke: 
  0.527 
Yes 
No 
126(90) 
 14(10) 
165(87.8) 
23(12.2) 
 
Pack years(mean ± SD) 5.4±6.8 3.4±4.8 0.002 
Co-morbidities:    
Allergies 99(70.7) 156(83) 0.008 
Coronary Artery diseases   17(12.1) 11(5.9) 0.044 
Chronic bronchitis 29 (20.7)  53(28.2) 0.122 
Sinusitis or nasal polyps 38(27.1)  65(34.6) 0.151 
Diabetes 13(9.3) 16(8.5) 0.807 
Hypertension 41(29.3)  44(23.4) 0.229 
High Cholesterol 25(17.9) 33(17.6) 0.943 
Heart Failure 4(2.9)  2(1.1) 0.231 
Arrhythmias 16(11.4) 28(14.9) 0.362 
Malignancy  6(4.3) 16 (8.5) 0.130 
Osteoporosis 7(5)  31(16.5) 0.001 
Depression  31(22.1)  73(38.8) 0.001 
Anxiety 29(20.7) 59(31.4) 0.031 
GERD/Heartburn  56(40) 86(45.7) 0.299 
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Anaemia  8(5.7)  34(18.1) 0.001 
Physical exam:    
weight(mean ±SD) 88.6±16.8 79.4±22.4 0.001 
height(mean ±SD) 172.9±8.8 161.7±7.0 0.001 
BMI (mean ±SD) 29.9±7.9 30.4±8.4 0.599 
Heart rate (mean ±SD) 73.8±11.2 76.1±11.7 0.067 
Respiratory rate (mean ±SD) 18.9±2.9 19.4±2.7 0.244 
Blood pressure (Systole) 126.3±17.1 123.6±19 0.185 
Blood pressure (Diastole) 78.9±11.6 76.7±10.4 0.067 
Oxygen saturation 95.4±1.9 96.0±2.1 0.007 
FEV1% predicted, m±SD 79.5±17.6 88.5±20.5 0.001 
FVC % predicted, m±SD 97.3±17.6 101.7±16.8 0.022 
FEV1/FVC 81.8±13.3 86.7±14.5 0.002 
PEF 93.0±24.7 105.6±25.6 0.02 
 
Table 3.3 Characteristics of 97 spirometrically-defined COPD individuals in the EPI-SOB 
Study, by sex. 
 Men 
#(%) 
Women 
#(%) 
p-value 
 
Patients 51(52.6) 46(47.4)  
Age in years (mean ± SD): 62.4±14.8 61.9±14.1 0.900 
AGE1   0.810 
Ages< 50 11(21.6) 9(19.6) 
 
Ages >50 40(78.4) 37(80.4)  
Marital status:     0.060 
Single/Never Married 
Separated/Divorced/Widowed 
Married/Common-Law 
 8(15.7) 
11(21.6) 
32(62.7) 
 7(15.2) 
20(43.5) 
19(41.3) 
 
Educational status:   0.315 
Post-Secondary Education  24(47.1)  17(37.0) 
 
Other 27(52.9) 29(63.0)  
Race:   0.487 
Caucasian 
Other  
43(84.3) 
8(15.7) 
 41(89.1) 
5(10.9) 
 
Smoking history:   0.464 
Current 
Past  
Never smoked  
 12(23.5) 
26(51.0) 
13(25.5) 
15(32.6)  
18(39.1) 
13(28.3) 
 
Second hand exposure to 
cigarette smoke: 
  0.253 
Yes 
No 
47(92.2) 
4(7.8) 
39(84.8) 
7(15.2) 
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Pack years(mean ± SD) 7.5±7.1 6.4±6.7 0.5 
Co-morbidities:    
Allergies 33(64.7) 37(80.4) 0.084 
Coronary Artery diseases  11(21.6) 7(15.2) 0.422 
Chronic bronchitis 12(23.5) 15(32.6) 0.319 
Sinusitis or nasal polyps 16(31.4) 18(39.1) 0.424 
Diabetes 7(13.7) 6(13.0) 0.922 
Hypertension 18(35.3) 21(45.7) 0.299 
High Cholesterol 13(25.5) 11(23.9) 0.857 
Heart Failure 2(3.9) 1(2.2) 0.620 
Arrhythmias 8(15.7) 10(21.7) 0.444 
Malignancy 4(7.8) 9(19.6) 0.091 
Osteoporosis 4(7.8) 19(41.3) 0.00 
Depression 12(23.5) 20(43.5) 0.037 
Anxiety 9(17.6) 15(32.6) 0.088 
GERD/Heartburn 19(37.3) 25(54.3) 0.091 
Anaemia 3(5.9) 5(10.9) 0.373 
Physical exam:    
BMI (mean ±SD) 29.2±5.1 30.6±10.1 0.360 
weight(mean ±SD) 86.9±14.1 77.7±27.8 0.039 
height(mean ±SD) 172.8±6.6 158.8±7.4 0.00 
Heart rate 73.1±11.9 78.2±13.0 0.047 
Respiratory rate 19.1±3.6 21.0±2.9 0.021 
Blood pressure(Systole) 129.9±18.5 130.6±19.5 0.868 
Blood pressure(Diastole) 79.2±10.9 78.9±10.1 0.953 
Oxygen saturation 94.6±2.1 94.3±2.5 0.458 
FEV1% predicted, m±SD 66.2±16.9 66.3±20.3 0.99 
FVC % predicted, m±SD 90.4±15.5 93±20.3 0.48 
FEV1/FVC 72.8±12.8 71.2±13.8 0.56 
PEF 79.3±23.8 80.8±24.3 0.75 
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Table 3.4 Characteristics of 149 spirometrically-defined asthma individuals in the EPI-SOB 
Study, by sex. 
 Men 
#(%) 
Women 
#(%) 
p-value 
 
Patients 62(41.6) 87(58.4)  
Age in years (mean ± SD): 44.9±16.6 41.7±17.3 0.3 
AGE1   0.382 
Ages< 50 37(59.7) 58(66.7)  
Ages >50 25(40.3) 29(33.3)  
Marital status:   0.935 
Single/Never Married 
Separated/Divorced/Widowed 
Married/CommonLaw 
20(32.3) 
3(4.8) 
39(62.9) 
26(29.9) 
5(5.7) 
56(64.4) 
 
Educational status:   0.515 
Post-Secondary Education 28(45.2) 44(50.6)  
Other 34(54.8) 43(49.4)  
Race:   0.002 
Caucasian 
Other  
48(77.4) 
14(22.6) 
82(94.3) 
5(5.7) 
 
Smoking history:   0.720 
Current 
Past  
Never smoked  
13(21.0) 
23(37.1) 
26(41.9) 
15(17.2) 
30(34.5) 
42(48.3) 
 
Second hand exposure to 
cigarette smoke: 
  0.997 
Yes 
No 
57(91.9) 
5(8.1) 
80(92.0) 
7(8.0) 
 
Pack years(mean ± SD) 5.7±7.7 3.0±4.3 0.007 
Co-morbidities:    
Allergies 53(85.5) 77(88.5) 0.586 
Coronary Artery diseases  2(3.2) 1(1.1) 0.374 
Chronic bronchitis 13(21) 22(25.3) 0.540 
Sinusitis or nasal polyps 16(25.8) 24(27.6) 0.809 
Diabetes 4(6.5) 6(6.9) 0.915 
Hypertension 16(25.8) 10(11.5) 0.023 
High Cholesterol 8(12.9) 8(9.2) 0.471 
Arrhythmias 6(9.7) 7(8.0) 0.728 
Malignancy 0(0) 4(4.6) 0.087 
Osteoporosis 1(1.6) 7(8.0) 0.086 
Depression 10(16.1) 28(32.2) 0.027 
Anxiety 10(16.1) 25(28.7) 0.074 
GERD/Heartburn 22(35.5) 34(39.1) 0.655 
Anaemia 3(4.8) 17(19.5) 0.009 
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Physical exam:    
BMI (mean ±SD) 30.5±10.1 29.6±8.1 0.557 
weight(mean ±SD) 89.5±17.5 78.6±21.1 0.001 
height(mean ±SD) 172.9±10.4 163.0±6.3 0.00 
Heart rate 74.6±10.9 75.5±11.9 0.642 
Respiratory rate 19.1±2.6 18.9±2.3 0.684 
Blood pressure(Systole) 124.9±15.1 118.8±15.3 0.019 
Blood pressure(Diastole) 79.7±11.1 75.4±10.2 0.017 
Oxygen saturation 95.4±1.9 96.6±1.7 0.000 
FEV1 % predicted, m±SD 79.9±15.6 92.4±15.4 0.00 
FVC % predicted, m±SD 99.1±18.6 104.5±13.3 0.042 
FEV1/FVC 81.2±12.8 88.1±12.6 0.001 
PEF 91.3±25.8 110.9±21.3 0.000 
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Table 3.5 Symptoms of men and women with spirometrically-defined COPD or asthma 
 COPD (n=97)  Asthma (n=146) 
 Men  
#(%) 
Women 
#(%) 
p-value  Men 
#(%) 
Women 
#(%) 
p-value 
MRC Dyspnea scale       0.298 
1-Not troubled by breathlessness 16(31.4) 10(21.7) 0.439  25(40.3) 25(28.7)  
2- Short of breath when hurrying on a 
level or when walking up a slight hill 
23(45.1) 19(41.3)   29(46.8) 48(55.2)  
3- Walks slower than most people on 
the level, stops after a mile or so, or 
stops after 15 minutes walking at own 
pace 
8(15.7) 13(28.3)   5(8.1) 12(13.8)  
4- Stops for breath after walking 100 
yards, or after a few minutes on level 
ground 
4(7.8) 4(8.7)   3(4.8) 2(2.3)  
MRC points%   0.149    0.589 
MRC 1-2 (mild dyspnea) 39(76.5) 29(63)   54(87.1) 73(83.9)  
MRC 3-4 (severe dyspnea) 12(23.5) 17(37)   8(12.9) 14(16.1)  
Cough symptoms        
Nocturnal cough 5(9.8) 8(17.4) 0.437  9(14.5) 10(11.5) 0.367 
Sputum production 9(17.6) 8(17.4) 0.222  11(17.7) 16(18.4) 0.943 
Chest tightness 8(15.7) 7(15.2) 0.885  16(25.8) 19(21.8) 0.617 
Wheeze 7(13.7) 14(30.4) 0.158  12(19.4) 19(21.8) 0.953 
Other symptoms        
Fatigue 6(11.8) 9(19.6) 0.552  9(14.5) 22(25.3) 0.039 
Recent hospitalization or ER visit 8(15.7) 13(28.3) 0.320  4(6.5) 17(19.5) 0.026 
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Table 3.6 COPD Assessment Test (CAT) scores for patients with spirometrically-defined COPD  
                                         COPD (n=97) 
CAT items.  Male, mean ±SD Female, mean ±SD p-value 
Cough all the time (0-5) 2.1±1.2 2.3±1.5 0.365 
Chest full of mucus (0-5) 2.1±1.6 2.4±1.5 0.508 
Chest feels very tight (0-5) 1.5±1.5 1.6±1.4 0.626 
Very breathless walking up hill (0-5) 2.4±1.6 3.1±1.6 0.04 
Limited doing activity (0-5) 1.4±1.5 2±1.8 0.125 
Not comfortable leaving home (0-5) 0.5±1.1 1.1±1.5 0.050 
Don’t sleep soundly (0-5) 1.5±1.5 1.6±1.7 0.862 
Have no energy (0-5) 2.3±1.3 2.9±1.6 0.061 
Total CAT SCORE 13.7±8.1 17±8.9 0.090 
0= no impact   5=maximum impact  
Table 3.7 Asthma Control Questionnaire (ACQ) scores for patients with spirometrically-defined asthma 
                             ASTHMA(n= 146)   
ACQ items Men, mean 
±SD 
Women, mean 
±SD 
p-value 
How often were you woken by asthma at night during the past week? (0-6) 0.5±1.0 0.7±1.0 0.382 
How bad were your asthma symptoms when you woke up in the morning 
(0-6) 
1.4±1.4 1.3±1.2 0.885 
How limited were you in your activities because of your asthma? (0-6) 1.0±1.2 1.0±1.2 0.951 
How much shortness of breath did you experience because of asthma? (0-
6) 
1.8±1.5 1.9±1.2 0.619 
How many times did you wheeze? (0-6) 2.1±1.6 1.5±1.4 0.030 
The number of puffs of short acting bronchodilator used each day? (0-6) 1.3±1.3 0.9±0.9 0.074 
TOTAL ACQ SCORE 7.5±5.4 7.4±5.1 0.920 
0=no impairment, 6= maximum impairment 
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Table 3.8 Inhaler medications used within the past 6 months for patients with spirometrically-defined COPD or asthma. 
 COPD (n=97)  Asthma (146) 
 Male Female p-value  Male Female p-value 
Anticholinergic, long-acting 10(19.6) 10(21.7) 0.796  3(4.8) 1(1.1) 0.170 
Anticholinergic, short-acting 5(9.8) 4(8.7) 0.851  2(3.2) 2(2.3) 0.730 
short-acting B2 agonist 34(66.7) 34(73.9) 0.436  45(72.6) 75(86.2) 0.038 
long-acting B2 agonist 4(7.8) 1(2.2) 0.207  2(3.2) 5(5.7) 0.473 
Inhaled corticosteroid 16(31.4) 8(17.4) 0.111  14(22.6) 28(32.2) 0.199 
Steroid oral 2(3.9) 1(2.2) 0.620  3(4.8) 5(5.7) 0.808 
Combination/symbicort 17(33.3) 20(43.5) 0.304  23(37.1) 31(35.6) 0.855 
Combination/Advair 18(35.3) 15(32.6) 0.780  18(29) 18(20.7) 0.241 
Theophylline(methylxanthine) 2(3.9) 2(4.3) 0.916  1(1.6) 0(0.0) 0.235 
Leukotriene receptor 
antagonists(LTRA) 
3(5.9) 4(8.7) 0.593  4(6.5) 8(9.2) 0.544 
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Table 3.9 Descriptives of family physician’s diagnosis of patients with spirometrically-defined COPD or asthma 
 Spirometrically-defined COPD   Spirometrically-defined Asthma  
Diagnostic 
outcomes 
All COPD 
patients(n=97) 
Men(n=51) Women(n=
46) 
p-value  All 
asthma 
patients(n
=146) 
Men 
(n=62) 
Women 
(n=87) 
p-value 
Ever given 
diagnosis for 
COPD by your 
GP? 
24(24.7) 11(21.6) 13(28.3) 0.446  9(6) 6(9.7) 3(3.4) 0.130 
Ever given 
diagnosis for 
asthma by 
your GP? 
45(46.4) 23(45.1) 22(47.8) 0.788  102(68.5) 46(74.2) 56(64.4) 0.203 
Ever referred 
to see a 
specialist by 
your GP? 
45(46.4) 22(43.1) 23(50) 0.499  40(26.8) 16(25.8) 24(27.6) 0.809 
Ever had a 
spirometry 
performed? 
49(50.5) 28(54.9) 21(45.7) 0.363  52(34.9) 27(43.5) 25(28.7) 0.062 
Ever had a 
chest x-ray 
performed? 
67(69.1) 33(64.7) 34(73.9) 0.327  58(38.9) 17(27.4) 41(47.1) 0.015 
Ever had 
methacholine 
test 
performed? 
2(2.1) 1(2.0) 1(2.2) 0.941  1(0.7) 1(1.6) 0(0) 0.235 
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Table 3.10 Univariate analysis for patients with spirometrically-defined COPD (Only p-values 
are presented in the table, see appendix c for output summary) 
Independent variable Outcome variables (p-values) 
 Physician-
diagnosed 
COPD 
Physician-
diagnosed 
asthma 
Referral to a 
specialist 
Referral for 
spirometry 
Referral for 
chest x-ray 
Sex 0.447 0.788 0.499 0.364 0.329 
Age 0.121 0.009 0.018 0.002 0.906 
Weight 0.200 0.301 0.200 0.713 0.864 
BMI 0.733 0.626 0.863 0.862 0.082 
Race 0.883 0.543 0.567 0.739 0.513 
Marital status 0.064 0.960 0.293 0.517 0.358 
Educational status 0.687 0.001 0.690 0.907 0.562 
Smoking history 0.071 0.078 0.883 0.890 0.493 
Pack years 0.252 0.748 0.673 0.669 0.934 
Second hand smoke 0.597 0.076 0.227 0.131 0.783 
FEV1% predicted 0.663 0.729 0.445 0.025 0.062 
FEV1/FVC 0.200 0.581 0.962 0.041 0.163 
PEF 0.345 0.378 0.539 0.768 0.806 
Oxygen saturation 0.707 0.577 0.420 0.492 0.050 
Systolic bp 0.391 0.499 0.646 0.313 0.069 
Heart rate 0.368 0.320 0.398 0.317 0.756 
Respiratory rate 0.452 0.332 0.666 0.017 0.009 
Total cat score 0.001 0.177 0.057 0.875 0.007 
dyspnoea 0.391 0.795 0.077 0.905 0.043 
 cough 0.069 0.401 0.701 0.119 0.102 
Sputum production 0.941 0.688 0.200 0.684 0.704 
Chest tightness 0.535 0.590 0.706 0.706 0.922 
Wheeze 0.706 0.058 0.961 0.943 0.793 
Fatigue 0.001 0.258 0.454 0.608 0.031 
Recent hospitalization   0.815 0.335 0.828 0.024 0.118 
Allergy 0.086 0.043 0.493 0.542 0.254 
Comorbidities 0.199 0.327 0.019 0.153 0.785 
Variables with p < 0.2 were included in the model 
 
 
 
 
 98 
Table 3.11 Multivariate analysis for patients with spirometrically-defined COPD  
Outcome variables  Female sex  (male=ref) 
Adjusted OR (95% CI) 
 
P-value 
Physician-diagnosed COPD 
(correct diagnosis) a 
0.862 (0.514-1.444) 0.573 
Physician-diagnosed asthma 
(misdiagnosis) b 
1.184 (0.486-2.887) 0.710 
Referral to a specialist c 1.265 (0.428-3.738) 0.671 
Referral for spirometry d 0.565 (0.160-1.994) 0.375 
Referral for chest x-ray e 0.625 (0.191-2.051) 0.438 
Explanatory variable is sex (male=ref) 
aAdjusted for: age, smoking history, cough, fatigue, total catscore. 
bAdjusted for: educational status, wheeze. 
cAdjusted for: age, total cat score, comorbidities. 
dAdjusted for: age, respiratory rate, comorbidities. 
eAdjusted for: respiratory rate, fatigue. 
 
 
 
 
Table 3.12 Univariate analysis for patients with spirometrically-defined asthma (Only p-values 
are presented in the table, see appendix c for output summary) 
Independent Variable Outcome  variables (p-value) 
 Physician-
diagnosed 
Asthma 
Physician-
diagnosed 
COPD 
Referral to a 
specialist 
Referral for 
spirometry 
Referral for 
chest x-ray 
Sex 0.205 0.131 0.809 0.063 0.016 
Age 0.092 0.007 0.021 0.006 0.815 
BMI 0.796 0.466 0.526 0.785 0.021 
Weight 0.382 0.185 0.949 0.626 0.561 
Race 0.292 0.880 0.545 0.404 0.097 
Marital status 0.926 0.664 0.390 0.028 0.148 
Educational status 0.046 0.126 0.046 0.701 0.312 
Smoking history 0.486 0.131 0.706 0.327 0.465  
Pack years 0.130 0.264 0.052 0.081 0.277 
Second hand exposure 
to cigarette smoke 
0.890 0.730 0.410 0.906 0.118 
FEV1% predicted 0.887 0.009 0.797 0.107 0.437 
FEV1/FVC 0.012 0.015 0.186 0.229 0.381 
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PEF 0.298 0.217 0.722 0.441  0.469 
Oxygen saturation 0.281 0.354 0.739 0.001 0.312 
Systolic bp 0.403 0.542 0.174 0.422 0.509 
Heart rate 0.555 0.941 0.467 0.325 0.116 
Respiratory rate 0.365 0.346 0.017 0.194 0.100 
Total ACQ score 0.566 0.020 0.800 0.614 0.318 
MRC dyspnoea 0.518 0.006 0.489 0.008 0.530 
cough 0.405 0.478 0.967 0.052 0.767 
Sputum production 0.664 0.346 0.872 0.967 0.059 
Chest tightness 0.410 0.962 0.869 0.695 0.533 
Wheeze 0.663 0.318 0.370 0.840 0.484 
Fatigue 0.031 0.669 0.232 0.608 0.260 
Recent hospitalization   0.945 0.531 0.536 0.345 0.054 
allergy 0.011 0.009 0.247 0.484 0.763 
comorbidities 0.006 0.019 0.034 0.017 0.014 
Variables with p < 0.2 were included in the model 
 
Table 3.13 Multivariate analysis for patients with spirometrically-defined asthma  
Outcome variables  Female sex (male=ref) 
Adjusted OR (95% CI) 
 
 
P-value 
Physician-diagnosed asthma 
(correct diagnosis)a 
0.535 (0.295-0.969) 
 
0.039* 
Physician-diagnosed COPD 
(misdiagnosis) b   
0.343 (0.067-1.756) 0.199 
Referral to a specialist c 0.871 (0.352-2.155) 0.765 
Referral for spirometry d 0.446 (0.200-0.994) 0.048* 
Referral for chest x-ray e 2.062 (1.030-4.128)  0.041* 
Explanatory variable is sex (male=ref) 
aAdjusted for: FEV1/FVC ratio, fatigue, allergy, comorbidities. 
bAdjusted for: FEV1/FVC ratio, dyspnea, allergy.   
cAdjusted for: packyears, respiratory rate, comorbidities. 
dAdjusted for: age, oxygen saturation, cough, dyspnea. 
eAdjusted for: BMI, heart rate, hospitalization, comorbidities.  
*Significant  
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Figure 3.1 Unadjusted frequencies for patients with spirometrically-defined COPD 
 101 
 
 
Figure 3.2 Unadjusted frequencies for patients with spirometrically-defined asthma 
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KEY 
1-not troubled by breathlessness except on strenuous 
exercise. 
2- short of breath when hurrying or walking up a 
slight hill. 
3- walks slower(than contemporaries) on level ground 
because of breathlessness or has to stop for breath 
when walking at own pace. 
4- stops for breath after walking about 100 meters or 
after a few minutes on level ground.  
5- too breathless to leave the house, or breathless 
when dressing/undressing .  
 
  
Figure 3.3 MRC Degree of dyspnoea for men and women with spirometrically-defined COPD. 
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KEY 
1-not troubled by breathlessness except on strenuous 
exercise. 
2- short of breath when hurrying or walking up a 
slight hill. 
3- walks slower(than contemporaries) on level 
ground because of breathlessness or has to stop for 
breath when walking at own pace. 
4- stops for breath after walking about 100 meters or 
after a few minutes on level ground.  
5- too breathless to leave the house, or breathless 
when dressing/undressing .  
 
 
Figure 3.4 MRC Degree of dyspnoea for men and women with spirometrically-defined asthma 
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CHAPTER FOUR 
Overall Discussion 
4.1 Summary of findings and discussion 
The aim of this research was to investigate gender disparities in the diagnosis of COPD 
and asthma from family physicians. To achieve this aim, we first conducted a systematic review 
and meta-analysis to objectively synthesize all the available evidence on this question. Based on 
the evidence provided by the review, we then investigated the presence or absence of gender 
disparities in a Canadian population, while addressing existing literature gaps.  
The findings from our first study (systematic review) revealed that women are less likely 
to be diagnosed with COPD by their family physicians and less likely to be referred for 
spirometry, even though they both may meet criteria for COPD. Our second study (secondary 
analysis) provided evidence that women with asthma are less likely to be given a diagnosis of 
asthma by their family physicians and less likely to be referred for spirometry, but more likely to 
be referred for chest x-rays. Comparing the two studies, referral for spirometry appears lower in 
women than men with obstructive airway diseases. Also, a correct diagnosis of COPD or of 
asthma appeared to have occurred more often in men than in women.  
Despite the growing cognizance of gender differences in health care, disparate treatment 
between men and women still exists for many chronic conditions (1). Even though some of these 
contrasts could be due to differences in disease presentation, prevalence and therapeutic 
response, a considerable number of studies have also shown evidence of gender bias leading to 
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systemic mistreatment (1, 2). In order to overcome gender bias, identifying the presence or 
otherwise of gender differences in patient care is imperative.  
 While the systematic review presuppose that gender differences exist in primary care for 
COPD, the secondary analysis of data corroborates the possible existence of gender disparities in 
the diagnosis of asthma as well, as we found women as less likely to be diagnosed with the 
condition and less likely to have had spirometry, but more likely to have had chest x-rays. It 
must be noted that gender biases may take different forms and may be consciously or 
unconsciously endorsed (3). Unconscious prejudices among physicians, coupled with social 
stereotyping have been identified as one of the stimuli for gender bias (2, 3). Also, when 
physicians underestimate or misunderstand a woman’s risk for health problems or complications, 
it may lead to biases (4). Moreover, there could be overt discrimination based on sex. For 
instance, when women’s symptoms are taken less seriously by physicians and attributed to 
emotional rather than physical causes, it may lead to less referrals for diagnostic tests and to 
gender bias (4). No one knows for sure which of these factor(s) leads to situations that appear to 
be gender bias. Different factors or combination of factors may influence different clinical 
scenarios.  
 Not everyone agrees that gender bias exists in health care. A physician once said that 
although “it is commonly believed that American health-care delivery and research benefit men 
at the expense of women, the truth appears to be exactly the opposite” (4, 5). He cited the longer 
life expectancy of women than men as evidence that “women receive more medical care and 
benefit more from medical research. The net result is the most important gap of all: seven years, 
10 percent of life” (4, 5). On the contrary, many more recent studies continue to provide 
evidence of gender bias in health care, which cuts across a wide spectrum of clinical practice 
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areas including cardiovascular diseases, airway diseases, surgery, orthopedics, behavioral health, 
as well as acute and critical care (6-11). It has been echoed that gender bias “need not be 
intentional to be detrimental, and in fact, the more insidious its existence, the more readily 
gender bias can invade, fester, and infect patient care in subtle and undetected ways”- JoAnn 
Grif Alspach, RN (4). Consequently, a bias in clinical diagnosis can hugely impact the health 
outcomes of patients (12). Results of the meta-analysis provided evidence of greater impairment 
in health-related quality of life and more dyspnoea in women than in men. However, the extent 
to which differences in symptoms and health outcomes of patients is reflected by gender bias in 
diagnosis and management was beyond the scope of our research. 
Besides issues of gender disparities, our research supports findings of other studies that: 
1. Underdiagnoses of both COPD and asthma is relatively high but higher for COPD than 
for asthma.  
2. A considerable number of people who meet spirometry criteria for COPD are often 
wrongly diagnosed as asthma by their family physicians.  
3. Spirometry -the recommended guidelines approved method of COPD and asthma 
diagnosis- is rarely used in primary care.  
4.  Chest x-rays are performed more often than spirometry. 
 There could be many reasons why underdiagnosis and misdiagnosis seem to be a major 
problem in primary care (13-15). The most apparent of all is diagnosis based mainly on patient 
history and clinical symptoms, without the use of spirometry (16-18). In a study by Herrera et al, 
underdiagnosis and misdiagnosis were less prevalent in those with previous spirometry (13). A 
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number of studies have shown evidence of spirometry underuse by general practitioners in 
establishing COPD diagnosis (19). In one of those studies, family physicians’ diagnosis of 
COPD was compared to that of chest physicians. The authors found that family physicians 
classified 29.3% of the patients correctly while chest physicians diagnosed 84.8% correctly (20). 
Lack of familiarity and lack of access or availability of the equipment could be determining 
factors for spirometry underuse in primary care.  
4.2 Strengths and limitations of the studies 
The systematic review included in this thesis has several strengths and limitations. The 
strengths include a comprehensive, systematic, and highly sensitive literature search conducted 
without restriction for language. To the best of our knowledge, the review represents the first 
meta-analysis of the association between gender and COPD diagnosis. We used standardized 
criteria to identify relevant articles and abstract pertinent data. To minimize error and study 
selection bias, two reviewers selected studies independently, with high interrater agreement. 
Included studies were rigorously evaluated using the USPSTF Quality Rating. We identified 
studies from America, Europe, and Asia, which increased the generalizability for most outcomes. 
The systematic review also has several important limitations. There is a possibility of 
publication bias for some of the outcomes, as funnel plots demonstrated possible existence of 
unpublished studies with negative results, which compromises findings of the systematic review. 
Also, including studies of “fair quality” in the analysis may have introduced bias and 
compromised findings of the study. Again, relatively few studies were identified for some 
primary outcomes at the meta-analysis stage, making it impractical to explore heterogeneity for 
those outcomes. A further shortcoming of the systematic review is reduced generalizability for 
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the outcome ‘physician-diagnosed COPD’, as all four studies that qualified for the meta-analysis 
were conducted in Spain.  
The second study presents with its own strengths and limitations. To the best of our 
knowledge, we investigated more outcomes than have ever been published by a single study on 
gender differences in obstructive airway diseases. Also, to the best of our knowledge, this is the 
first study to dissect gender bias in the diagnosis of asthma, and the first study to consider gender 
disparities in a Canadian setting, using real life population. The findings of the study have 
provided valuable information that could be used to develop hypothesis for further research.  
Findings from this study may however be limited in several ways. Participants were 
adults, and as such, results from the study may not be applicable to children and people under 
40years of age. The cohort may also not be representative of the entire COPD/asthma population 
at large. Our cohort of patients appeared to have mild disease, and this may have impacted the 
findings of the study. Also, there were considerable differences between men and women at 
baseline. Although variables that were found to be strongly associated with the outcomes were 
controlled for in multivariate analysis, there could be some other unknown physiological and 
environmental factors causing residual confounding. Moreover, some sub-analyses recorded very 
small numbers of respondents and that may have impacted the results. Again, the many statistical 
tests increase the probability of a type I error. Another limitation of the study is the self-response 
nature of primary outcomes. Even though outcomes were crosschecked with patients’ records, 
we cannot rule out recall bias.  
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4.3 Clinical Implications 
Discrepancies in care between men and women mean that necessary diagnostic 
procedures may not be performed, specialty referrals may not be made, and medications not 
prescribed, all of which can impact outcomes. Evidence obtained from this research can increase 
awareness of a possible existence of differences in care given to men and women, which is an 
important step in reducing gender bias and facilitating early recognition of disease in men and 
women. Our findings also highlight the importance of encouraging the use of objective methods 
of diagnosis in primary care, as this may greatly reduce discrepancies and bias. 
4.4. Conclusion 
Available guidelines for COPD and asthma care and management do not differ for men 
and women. Results of the meta-analysis however provided evidence of differences in diagnostic 
procedures for men and women with COPD, with less appropriate diagnostic work-up for 
women. Discrepancies between men and women were also identified for some diagnostic 
procedures for asthma. These differences persisted after accounting for potential confounders, 
and may imply an underlying gender bias in COPD/asthma care. Nonetheless, due to 
considerable number of study limitations and inability to corroborate results for COPD in a 
Canadian setting, the findings of this project should be interpreted cautiously. We still require 
more well-conducted studies of higher quality and with larger sample sizes to draw more 
meaningful conclusions. Also, more studies need to be conducted across jurisdictions to increase 
generalizability and precision. Future studies may subsequently explore the reasons behind these 
observed differences in order to make corrective measures more targeted.  As healthcare systems 
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continue to explore various means to improve patient care, attention should also be channeled 
towards promoting equal care for men and women. 
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APPENDIX A: Detailed search strategy for systematic review and 
meta-analysis and sensitivity analysis 
 
Database Search string 
PubMed ("Pulmonary Disease, Chronic Obstructive"[Mesh] OR COPD[tiab] OR 
"chronic obstructive pulmonary disease"[tiab]) AND ("Sexism"[Mesh] 
OR "gender difference"[tiab] OR "gender differences"[tiab] OR "gender 
factor"[tiab] OR "gender factors"[tiab] OR "gender bias"[tiab] OR "sex 
bias"[tiab]) "[Mesh] OR "risk factor"[tiab] OR "risk factors"[tiab]) 
 
Embase ('chronic obstructive lung disease'/de OR copd:ab,ti OR 'chronic 
obstructive pulmonary disease':ab,ti) AND ('sexism'/exp OR 'gender 
difference':ab,ti OR 'gender differences':ab,ti OR 'gender factor':ab,ti OR 
'gender factors':ab,ti OR 'gender bias':ab,ti OR 'sex bias':ab,ti) 
  
 
Cinahl (MH "Pulmonary Disease, Chronic Obstructive+" OR TI COPD OR AB 
COPD OR TI "chronic obstructive pulmonary disease" OR AB "chronic 
obstructive pulmonary disease") AND (MH "Sexism" OR MH "Gender 
Bias" OR MH "Gender Specific Care" OR MH "Sex Factors" OR TI 
"gender difference" OR AB "gender difference" OR TI "gender 
differences" OR AB "gender differences" OR TI "gender factor" OR AB 
"gender factor" OR TI "gender factors" OR AB "gender factors" OR TI 
"gender bias" OR AB "gender bias" OR TI "sex bias" OR AB "sex bias")  
  
 
 
 
 
 
 
Sensitivity analysis for forest plot assessing whether women are less likely than men to be 
referred for spirometry. 
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APPENDIX B: HREB approval letter 
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APPENDIX C:  Spss output summary for univariate analysis 
a. Univariate analysis for patients with spirometrically-defined COPD  
i. Dependent variable: Physician-diagnosed COPD (correct diagnosis)  
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .359 .472 .579 1 .447 1.433 .568 3.616 
Constant -1.291 .340 14.379 1 .000 .275   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age .028 .018 2.407 1 .121 1.029 .993 1.066 
Constant -2.908 1.207 5.808 1 .016 .055   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nweight -.013 .010 1.690 1 .200 .987 .967 .993 
Constant -.054 .965 .003 1 .955 .947   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmarital -.578 .312 3.436 1 .064 .561 .304 1.034 
Constant .215 .734 .086 1 .770 1.240   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsmoking -.603 .334 3.251 1 .071 .547 .284 1.054 
Constant .037 .656 .003 1 .955 1.038   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tff_pr2 -.015 .012 1.563 1 .200 .985 .963 .992 
Constant -.023 1.280 .000 1 .986 .977   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
ncough_n -.463 .254 3.311 1 .069 .629 .382 1.036 
Constant .429 .863 .248 1 .619 1.536   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nfatigue -1.012 .317 10.176 1 .001 .363 .195 .677 
Constant 2.132 1.013 4.429 1 .035 8.432   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nallergy .856 .498 2.951 1 .086 2.353 .886 6.246 
Constant -2.242 .718 9.742 1 .002 .106   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Comorbidities -.134 .104 1.653 1 .199 .875 .713 1.073 
Constant 2.360 2.694 .767 1 .381 10.586   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
dtotal .115 .036 10.321 1 .001 1.121 1.046 1.203 
Constant -3.048 .722 17.819 1 .000 .047   
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ii. Dependent variable: Physician-diagnosed asthma (misdiagnosis) 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .110 .408 .072 1 .788 1.116 .502 2.482 
Constant -.197 .281 .489 1 .485 .821   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age -.041 .016 6.849 1 .009 .960 .931 .990 
Constant 2.411 1.001 5.804 1 .016 11.148   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_neducat -1.404 .436 10.356 1 .001 .246 .104 .578 
Constant 2.061 .718 8.234 1 .004 7.852   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsmoking .501 .284 3.105 1 .078 1.650 .945 2.879 
Constant -1.145 .607 3.560 1 .059 .318   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
n2ndhand 1.262 .711 3.148 1 .076 3.532 .876 14.234 
Constant -1.543 .805 3.672 1 .055 .214   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a nwheeze -.489 .258 3.598 1 .058 .613 .370 1.016 
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Constant 1.349 .814 2.749 1 .097 3.854   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nallergy -.979 .485 4.083 1 .043 .376 .145 .971 
Constant 1.094 .638 2.940 1 .086 2.986   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
dtotal -.038 .028 1.820 1 .177 .963 .911 1.017 
Constant .303 .476 .405 1 .524 1.354   
 
 
iii. Dependent variable: Referral to a specialist  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .276 .409 .457 1 .499 1.318 .592 2.936 
Constant -.276 .283 .955 1 .329 .759   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age .037 .016 5.574 1 .018 1.038 1.006 1.070 
Constant -2.468 1.015 5.917 1 .015 .085   
  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nweight -.012 .010 1.524 1 .200 .988 .969 1.007 
Constant .843 .822 1.051 1 .305 2.323   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
dtotal .054 .028 3.613 1 .057 1.055 .998 1.115 
Constant -1.034 .495 4.359 1 .037 .355   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmrc_c .417 .236 3.135 1 .077 1.518 .956 2.410 
Constant -1.030 .542 3.614 1 .057 .357   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsputum .315 .248 1.618 1 .200 1.370 .843 2.227 
Constant -1.169 .834 1.962 1 .161 .311   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
comorbidities -.225 .096 5.465 1 .019 .798 .661 .964 
Constant 5.730 2.521 5.168 1 .023 308.085   
 
 
iv. Dependent variable: Referral for spirometry 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.371 .408 .825 1 .364 .690 .310 1.536 
Constant .197 .281 .489 1 .485 1.217   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age .050 .017 9.185 1 .002 1.051 1.018 1.086 
Constant -3.106 1.061 8.576 1 .003 .045   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
ncough_n .381 .244 2.436 1 .119 1.463 .907 2.359 
Constant -1.281 .863 2.203 1 .138 .278   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
n2ndhand 1.074 .711 2.284 1 .131 2.927 .727 11.783 
Constant -1.167 .803 2.112 1 .146 .311   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nhosp .428 .190 5.100 1 .024 1.535 1.058 2.226 
Constant -1.369 .656 4.352 1 .037 .254   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nresprt -.209 .088 5.667 1 .017 .812 .684 .964 
Constant 3.700 1.742 4.512 1 .034 40.463   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
comorbidities -.132 .092 2.038 1 .153 .877 .732 1.050 
Constant 3.456 2.416 2.046 1 .153 31.679   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tfev_pr2 -.027 .012 5.025 1 .025 .974 .951 .997 
Constant 1.766 .814 4.705 1 .030 5.849   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tff_pr2 -.019 .009 4.185 1 .041 .982 .964 .999 
Constant 1.494 .760 3.867 1 .049 4.454   
 
v. Dependent variable: Referral for chest x-ray 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .435 .446 .954 1 .329 1.545 .645 3.702 
Constant .606 .293 4.279 1 .039 1.833   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
BMI .062 .036 3.016 1 .082 1.064 .992 1.141 
Constant -.998 1.036 .927 1 .336 .369   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tfev_pr2 -.023 .013 3.479 1 .062 .977 .953 1.001 
Constant 2.422 .896 7.302 1 .007 11.265   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a tff_pr2 -.025 .018 1.945 1 .163 .975 .942 1.010 
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Constant 2.648 1.333 3.949 1 .047 14.129   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
no2sat -.223 .114 3.839 1 .050 .800 .640 1.000 
Constant 21.957 10.824 4.115 1 .042 5.849   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nbpsys .024 .013 3.316 1 .069 1.025 .998 1.052 
Constant -2.281 1.706 1.788 1 .181 .102   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nresprt .244 .093 6.880 1 .009 1.277 1.064 1.533 
Constant -4.180 1.830 5.220 1 .022 .015   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
dtotal .091 .034 7.398 1 .007 1.096 1.026 1.170 
Constant -.757 .511 2.195 1 .138 .469   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmrc_c .551 .273 4.078 1 .043 1.734 1.016 2.960 
Constant -.313 .575 .296 1 .587 .731   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a ncough_n -.487 .298 2.667 1 .102 .614 .342 1.102 
 124 
Constant 2.503 1.087 5.301 1 .021 12.219   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nfatigue -.725 .336 4.652 1 .031 .485 .251 .936 
Constant 3.287 1.202 7.474 1 .006 26.761   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nhosp -.337 .216 2.437 1 .118 .714 .468 1.090 
Constant 1.920 .768 6.248 1 .012 6.821   
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b. Univariate analysis for patients with spirometrically-defined asthma  
i. Dependent variable: Physician-diagnosed asthma (correct diagnosis)  
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.465 .367 1.607 1 .205 .628 .306 1.289 
Constant 1.056 .290 13.239 1 .000 2.875   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age -.024 .014 2.939 1 .092 .976 .976 1.004 
Constant 1.856 .510 13.235 1 .000 6.398   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_neducat -.725 .363 3.996 1 .046 .484 .238 .986 
Constant 1.899 .602 9.948 1 .002 6.681   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
packyears -.056 .037 2.291 1 .130 .945 .878 .983 
Constant 1.021 .222 21.237 1 .000 2.776   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tff_pr2 -.020 .015 1.777 1 .012 .980 .965 .996 
Constant 2.482 1.314 3.568 1 .059 11.963   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nfatigue -.282 .131 4.634 1 .031 .754 .583 .974 
Constant 1.708 .761 5.034 1 .025 5.520   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nallergy -1.278 .504 6.424 1 .011 .279 .104 .748 
Constant 2.238 .608 13.553 1 .000 9.375   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Comorbidities .207 .075 7.618 1 .006 1.230 1.061 1.426 
Constant -4.967 2.702 3.380 1 .066 .007   
 
ii. Dependent variable: Physician-diagnosed COPD (misdiagnosis)  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -1.099 .728 2.278 1 .131 .333 .080 1.388 
Constant -2.234 .430 27.037 1 .000 .107   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age .062 .023 7.172 1 .007 1.064 1.017 1.114 
Constant -5.924 1.400 17.911 1 .000 .003   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nweight .020 .015 1.759 1 .185 1.020 .991 1.050 
Constant -4.456 1.394 10.216 1 .001 .012   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_neducat 1.253 .819 2.337 1 .126 3.500 .702 17.440 
Constant -4.808 1.488 10.440 1 .001 .008   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsmoking -.670 .444 2.277 1 .131 .512 .215 1.221 
Constant -1.343 .919 2.136 1 .144 .261   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tfev_pr2 -.047 .018 6.754 1 .009 .954 .920 .988 
Constant 1.090 1.407 .601 1 .438 2.975   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tff_pr2 -.049 .020 5.928 1 .015 .952 .916 .991 
Constant 1.195 1.566 .582 1 .445 3.303   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
totalacqscore .184 .079 5.386 1 .020 1.202 1.029 1.404 
Constant -4.576 1.010 20.517 1 .000 .010   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmrc_c 1.128 .412 7.490 1 .006 3.089 1.377 6.926 
Constant -5.166 1.069 23.349 1 .000 .006   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nallergy 1.897 .724 6.860 1 .009 6.667 1.612 27.572 
Constant -5.116 1.072 22.786 1 .000 .006   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
comorbidities -.412 .176 5.481 1 .019 .662 .469 .935 
Constant 8.483 4.694 3.267 1 .071 4831.818   
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Dependent variable: Referral to a specialist   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nweight .020 .015 1.759 1 .185 1.020 .991 1.050 
Constant -4.456 1.394 10.216 1 .001 .012   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_neducat 1.253 .819 2.337 1 .126 3.500 .702 17.440 
Constant -4.808 1.488 10.440 1 .001 .008   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsmoking -.670 .444 2.277 1 .131 .512 .215 1.221 
Constant -1.343 .919 2.136 1 .144 .261   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tfev_pr2 -.047 .018 6.754 1 .009 .954 .920 .988 
Constant 1.090 1.407 .601 1 .438 2.975   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tff_pr2 -.049 .020 5.928 1 .015 .952 .916 .991 
Constant 1.195 1.566 .582 1 .445 3.303   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a totalacqscore .184 .079 5.386 1 .020 1.202 1.029 1.404 
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Constant -4.576 1.010 20.517 1 .000 .010   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmrc_c 1.128 .412 7.490 1 .006 3.089 1.377 6.926 
Constant -5.166 1.069 23.349 1 .000 .006   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nallergy 1.897 .724 6.860 1 .009 6.667 1.612 27.572 
Constant -5.116 1.072 22.786 1 .000 .006   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
comorbidities -.412 .176 5.481 1 .019 .662 .469 .935 
Constant 8.483 4.694 3.267 1 .071 4831.818   
 
 
iii. Dependent variable: Referral to a specialist  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .091 .377 .058 1 .809 1.095 .524 2.291 
Constant -1.056 .290 13.239 1 .000 .348   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age -.024 .011 5.397 1 .021 .976 .956 .996 
Constant 1.856 .510 13.235 1 .000 6.398   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_neducat -.725 .363 3.996 1 .046 .484 .238 .986 
Constant 1.899 .602 9.948 1 .002 6.681   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
packyears -.056 .029 3.768 1 .052 .945 .893 1.001 
Constant 1.021 .222 21.237 1 .000 2.776   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tff_pr2 -.020 .015 1.747 1 .186 .980 .952 1.010 
Constant 2.482 1.314 3.568 1 .059 11.963   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
  nbpsys .135 .099 1.847 1 .174 1.144 .942 1.389 
Constant -1.504 1.858 .655 1 .418 .222   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nresprt -.028 .012 5.700 1 .017 .972 .950 .995 
Constant 4.240 1.468 8.340 1 .004 69.397   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a comorbidities .207 .097 4.505 1 .034 1.230 1.016 1.488 
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Constant -4.967 2.702 3.380 1 .066 .007   
 
iv. Dependent variable: Referral for spirometry   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.649 .349 3.457 1 .063 .523 .264 1.036 
Constant -.260 .256 1.026 1 .311 .771   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age .047 .011 17.566 1 .006 1.048 1.025 1.071 
Constant -2.727 .550 24.601 1 .000 .065   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmarital .449 .204 4.848 1 .028 1.566 1.051 2.336 
Constant -1.697 .531 10.209 1 .001 .183   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
packyears .050 .029 3.050 1 .081 1.051 .994 1.112 
Constant -.837 .214 15.319 1 .000 .433   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
tfev_pr2 -.011 .007 2.593 1 .107 .989 .975 1.002 
Constant .517 .724 .511 1 .475 1.678   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
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Step 1a 
no2sat -.351 .108 10.507 1 .001 .704 .569 .870 
Constant .260 .256 1.026 1 .311 .771 -.260 .256 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nresprt .122 .094 1.684 1 .194 1.129 .940 1.357 
Constant -3.250 1.813 3.213 1 .073 .039   
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmrc_c .641 .240 7.143 1 .008 1.899 1.187 3.040 
Constant -1.836 .494 13.807 1 .000 .160   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
ncough_n -.352 .181 3.787 1 .052 .703 .493 1.003 
Constant .532 .614 .752 1 .386 1.703   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
comorbidities -.230 .096 5.699 1 .017 .794 .658 .960 
Constant 5.777 2.680 4.648 1 .031 322.819   
 
 
v. Dependent variable: Referral for chest x-ray  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .858 .357 5.794 1 .016 2.359 1.173 4.746 
Constant -.973 .285 11.692 1 .001 .378   
 134 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
BMI .055 .024 5.364 1 .021 1.056 1.008 1.106 
Constant -2.094 .727 8.295 1 .004 .123   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
race -.980 .590 2.757 1 .097 .375 .118 1.193 
Constant .638 .666 .919 1 .338 1.893   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
d_nmarital .275 .190 2.096 1 .148 1.316 .907 1.908 
Constant -1.098 .484 5.153 1 .023 .334   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
n2ndhand -1.240 .794 2.441 1 .118 .289 .061 1.371 
Constant .871 .849 1.053 1 .305 2.390   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nheartrt -.024 .015 2.476 1 .116 .976 .948 1.006 
Constant 1.358 1.144 1.409 1 .235 3.888   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nresprt .149 .090 2.699 1 .100 1.160 .972 1.385 
Constant -3.290 1.740 3.576 1 .059 .037   
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsputum -.333 .176 3.578 1 .059 .717 .508 1.012 
Constant .600 .577 1.081 1 .298 1.823   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nhosp -.273 .142 3.703 1 .054 .761 .577 1.005 
Constant .422 .481 .770 1 .380 1.526   
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
comorbidities -.235 .096 6.035 1 .014 .791 .655 .954 
Constant 6.092 2.664 5.228 1 .022 442.088   
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APPENDIX D:  Spss output summary for multivariate analysis 
using the backward elimination method for final models 
a. Final models for patients with spirometrically-defined COPD  
 
i. Dependent variable: Physician-diagnosed COPD (correct diagnosis) 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.149 .263 .321 1 .573 .862 .514 1.444 
Age .068 .027 6.395 1 .011 1.071 1.015 1.129 
nsmoking -.766 .391 3.838 1 .050 .465 .216 1.000 
ncough_n -.493 .311 2.505 1 .049 .611 .332 .978 
nfatigue -1.277 .362 12.408 1 .000 .279 .137 .568 
dtotal .110 .043 6.419 1 .011 1.116 1.025 1.216 
Constant 2.816 2.157 1.705 1 .192 16.711   
 
ii. Dependent variable: Physician-diagnosed asthma (misdiagnosis) 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .169 .455 .138 1 .710 1.184 .486 2.887 
d_neducat -1.691 .479 12.475 1 .001 .184 .072 .471 
nwheeze -.698 .287 5.919 1 .015 .497 .283 .873 
Constant 4.552 1.334 11.648 1 .001 94.799   
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iii. Dependent variable: Referral to a specialist 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .235 .553 .180 1 .671 1.265 .428 3.738 
Age .045 .021 4.620 1 .032 1.046 1.004 1.090 
dtotal .062 .032 3.754 1 .050 1.064 1.000 1.132 
comorbidities -.256 .131 3.819 1 .050 .774 .599 1.000 
Constant 2.556 3.954 .418 1 .518 12.889   
 
iv. Dependent variable: Referral for spirometry 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.572 .644 .788 1 .375 .565 .160 1.994 
Age .055 .024 5.105 1 .024 1.056 1.007 1.108 
nresprt -.236 .105 5.026 1 .025 .790 .642 .971 
comorbidities -.335 .151 4.932 1 .026 .715 .532 .961 
Constant .462 2.120 .048 1 .827 1.588   
 
 
v. Dependent variable: Referral for chest x-ray 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.470 .606 .601 1 .438 .625 .191 2.051 
nresprt .268 .102 6.922 1 .009 1.307 1.071 1.596 
nfatigue -.814 .414 3.876 1 .049 .443 .197 .996 
Constant -1.542 2.345 .433 1 .511 .214   
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b. Final models for patients with spirometrically-defined asthma 
i. Dependent variable: Physician-diagnosed asthma (correct diagnosis) 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.625 .303 4.255 1 .039 .535 .295 .969 
tff_pr2 -.576 .294 3.838 1 .050 .562 .3158 1.000 
nfatigue -.470 .239 3.867 1 .049 .625 .391 .998 
nallergy -1.177 .552 4.546 1 .033 .308 .104 .909 
comorbidities .223 .072 9.593 1 .002 1.250 1.085 1.4399 
Constant -1.275 3.115 .168 1 .682 .279   
 
 
ii. Dependent variable: Physician-diagnosed COPD (misdiagnosis) 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -1.070 .833 1.649 1 .199 .343 .067 1.756 
tff_pr2 -.062 .025 5.911 1 .015 .940 .894 .988 
d_nmrc_c 1.074 .489 4.819 1 .028 2.928 1.122 7.639 
nallergy 2.557 .959 7.102 1 .008 12.894 1.967 84.530 
Constant -2.840 2.111 1.809 1 .179 .058   
 
 
iii. Dependent variable: Referral to a specialist 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.138 .462 .090 1 .765 .871 .352 2.155 
packyears -.767 .407 3.554 1 .050 .465 .209 1.000 
nresprt -.236 .096 6.006 1 .014 .790 .654 .954 
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comorbidities -.230 .103 4.986 1 .026 .795 .650 .973 
Constant 2.312 4.534 .260 1 .610 10.099   
 
 
iv. Dependent variable: Referral for spirometry 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) -.807 .409 3.904 1 .048 .446 .200 .994 
Age .062 .019 10.648 1 .001 1.064 1.025 1.104 
no2sat -.034 .015 5.138 1 .025 .966 .938 .996 
ncough_n -.357 .182 3.848 1 .050 .700 .490 .700 
d_nmrc_c .436 .216 4.074 1 .043 1.547 1.014 2.361 
Constant 1.721 1.931 .794 1 .373 5.588   
 
v. Dependent variable: Referral for chest x-ray 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
nsexn(1) .724 .354 4.183 1 .041 2.062 1.030 4.128 
BMI .056 .025 4.993 1 .025 1.058 1.007 1.111 
nheartrt -.036 .017 4.457 1 .035 .965 .933 .997 
nhosp -.334 .158 4.487 1 .034 .716 .526 .975 
comorbidities -.241 .110 4.827 1 .028 .785 .633 .974 
Constant 7.900 3.751 4.435 1 .035 26.451   
 
 
 
 
